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Abstract
Background
According to the latest revised National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) (NINCDS-ADRDA)
diagnostic criteria for Alzheimer's disease dementia, the confidence in diagnosing mild cognitive impairment (MCI) due to
Alzheimer's disease dementia is raised with the application of imaging biomarkers. These tests, added to core clinical
criteria, might increase the sensitivity or specificity of a testing strategy. However, the accuracy of biomarkers in the
diagnosis of Alzheimer’s disease dementia and other dementias has not yet been systematically evaluated. A formal
systematic evaluation of the sensitivity, specificity, and other properties of positron emission tomography (PET) imaging with
the 11C-labelled Pittsburgh Compound-B (11C-PIB) ligand was performed.
Objectives
To determine the diagnostic accuracy of the 11C-PIB-PET scan for detecting participants with MCI at baseline who will
clinically convert to Alzheimer’s disease dementia or other forms of dementia over a period of time.
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Search methods
The most recent search for this review was performed on 12 January 2013. We searched MEDLINE (OvidSP), EMBASE
(OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science and Conference Proceedings (ISI Web of Knowledge),
PsycINFO (OvidSP), and LILACS (BIREME). We also requested a search of the Cochrane Register of Diagnostic Test
Accuracy Studies (managed by the Cochrane Renal Group).
No language or date restrictions were applied to the electronic searches and methodological filters were not used so as to
maximise sensitivity.
Selection criteria
We selected studies that had prospectively defined cohorts with any accepted definition of MCI with baseline 11C-PIB-PET
scan. In addition, we only selected studies that applied a reference standard for Alzheimer's dementia diagnosis for example
NINCDS-ADRDA or Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria.
Data collection and analysis
We screened all titles generated by electronic database searches. Two review authors independently assessed the abstracts
of all potentially relevant studies. The identified full papers were assessed for eligibility and data were extracted to create two
by two tables. Two independent assessors performed quality assessment using the QUADAS 2 tool. We used the
hierarchical summary receiver operating characteristic (ROC) model to produce a summary ROC curve.
Main results
Conversion from MCI to Alzheimer's disease dementia was evaluated in nine studies. The quality of the evidence was
limited. Of the 274 participants included in the meta-analysis, 112 developed Alzheimer’s dementia. Based on the nine
included studies, the median proportion converting was 34%. The studies varied markedly in how the PIB scans were done
and interpreted.
The sensitivities were between 83% and 100% while the specificities were between 46% and 88%. Because of the variation
in thresholds and measures of 11C-PIB amyloid retention, we did not calculate summary sensitivity and specificity. Although
subject to considerable uncertainty, to illustrate the potential strengths and weaknesses of 11C-PIB-PET scans we estimated
from the fitted summary ROC curve that the sensitivity was 96% (95% confidence interval (CI) 87 to 99) at the included study
median specificity of 58%. This equated to a positive likelihood ratio of 2.3 and a negative likelihood ratio of 0.07. Assuming
a typical conversion rate of MCI to Alzheimer’s dementia of 34%, for every 100 PIB scans one person with a negative scan
would progress and 28 with a positive scan would not actually progress to Alzheimer’s dementia.
There were limited data for formal investigation of heterogeneity. We performed two sensitivity analyses to assess the
influence of type of reference standard and the use of a pre-specified threshold. There was no effect on our findings.
Authors' conclusions
Although the good sensitivity achieved in some included studies is promising for the value of 11C-PIB-PET, given the
heterogeneity in the conduct and interpretation of the test and the lack of defined thresholds for determination of test
positivity, we cannot recommend its routine use in clinical practice.11C-PIB-PET biomarker is a high cost investigation,
therefore it is important to clearly demonstrate its accuracy and standardise the process of the 11C-PIB diagnostic modality
prior to it being widely used.
Plain language summary
11C-PIB-PET scan for early prediction of developing Alzheimer’s disease or other dementia in people with mild
cognitive impairment (MCI)
The numbers of people with dementia and other cognitive problems are increasing globally. A diagnosis of the pre-dementia
phase of disease is recommended but there is no agreement on the best approach. A range of tests have been developed
which healthcare professionals can use to assess people with poor memory or cognitive impairment. Based on the published
data, we have found that the 11C-PIB-PET scan as a single test lacks the accuracy to identify those patients with MCI who
would develop Alzheimer's disease dementia or other forms of dementia. The findings indicate that for every 100 PIB scans,
one person with a negative scan will progress to Alzheimer's disease dementia and 28 with a positive scan will not.
Therefore, a positive PIB scan in patients with MCI is of no clinical value in the early prediction of Alzheimer's disease
dementia developing.
Background 
The pathology of Alzheimer’s disease is present in the majority of cases of dementia. As the dominant or sole
pathology, it accounts for over 50% of dementia, afflicting 5% of men and 6% of women over the age of 60 years
worldwide (World Health Organization 2002). However, the strength of the link between cognitive impairment and the
pathological features of Alzheimer’s disease varies with age and with each of the different pathological features. It
has also been recognised that a significant number of individuals without clinical evidence of Alzheimer’s disease
have amyloid deposition at death (Dickson 1992). Indeed, epidemiological neuropathological studies have established
that there is no significant relationship between amyloid plaque burden and cognitive impairment in those over the age
of 90 years (Savva 2009).
The term 'Alzheimer’s disease dementia' is used to describe those in whom the symptoms of cognitive impairment have
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gradually progressed to the point where the ability of the patient to perform everyday functions has been affected. Before
this, there is a stage, known as mild cognitive impairment (MCI), in which the patient has a degree of cognitive impairment
which is greater than expected for age but he or she is not impaired in function. Before MCI, there is a stage in which the
pathology is present and increasing but has not yet affected cognitive function, known as 'preclinical Alzheimer’s disease'. 
MCI is a heterogeneous condition. In this review MCI refers to the clinical criteria defined by Petersen or the revised
Petersen criteria (Petersen 1999; Petersen 2004; Winblad 2004), the Cognitive Dementia Rating (CDR = 0.5) scale (Morris
1993), or to the 16 different classifications of MCI (Matthews 2008). There are four outcomes for those within an MCI
population, progression to Alzheimer's disease dementia, progression to another dementia, maintaining stable MCI, or
recovery. At present, there is no clinical method to determine who of these patients will experience Alzheimer's disease
dementia (ADD) or other forms of dementia.
The main concern of patients who present with worries about their cognitive function is whether there is a treatment
which will either improve or delay progression of their symptoms. The rate at which patients cross the boundary
between preclinical Alzheimer’s disease and MCI, and between MCI and Alzheimer's disease dementia, depends
on several factors. Patients presenting to primary care are different from those in secondary care, who are different
again from those in research settings. Those with the apolipoprotein E4 (ApoE4) genotype progress more
rapidly. Within the 'MCI band', those with worse cognitive function also progress more rapidly. Studies indicate that
an annual average of 5% to 15% of MCI patients progress to ADD (Petersen 1999; Bruscoli 2004; Mattsson 2009; Petersen
2009).
Alzheimer’s disease pathology is associated with cerebral amyloidosis and the presence of amyloid-beta (Abeta)
plaques and neurofibrillary tangles in brain tissues at autopsy has been considered a 'gold standard' for the definitive
diagnosis of Alzheimer’s disease ( Mirra 1991; Newell 1999). However, Abeta plaques are present in conditions
other than ADD (Villemagne 2008). Abeta amyloid deposits, measured with a Pittsburgh Compound-B (PIB)
radioactive substance, are greater in congophilic angiopathy (Johnson 2007) and dementias other than ADD. PIB
retention and Abeta imaging in vivo could indicate more accurate differential diagnosis of the dementias. For
instance, PIB could differentiate Alzheimer's disease from frontotemporal dementia (FTD) (Rabinovici 2007; Rowe 2007; 
Drzezga 2008; Engler 2008). The role of the PIB positron emission tomography (PET) biomarker in dementia differential
diagnostics is being evaluated in a number of separate Cochrane systematic reviews. 
The U.S. Food and Drug Administration (FDA) position on recently licensed amyloid
ligands is that such tests do not establish a positive diagnosis of Alzheimer's disease
nor, if positive, predict progression from MCI to ADD (http://www.alzforum.org/news/research-news/fda-approves-second-
amyloid-imaging-agent; http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm372261.htm).
It is a reasonable assumption, and one on which this review is predicated, that if a patient has both MCI and the pathology of
Alzheimer's disease and then goes on to develop clinical ADD then the cause of the initial MCI and of the ADD was the
Alzheimer’s pathology. 
Our approach is an example of assessing diagnostic accuracy using delayed verification of diagnosis. Instead of the
reference standard being based on pathology, however, it is based on a clinical standard, the progression from MCI to ADD
or other dementias. Although, for the reasons stated above, this introduces a degree of unreliability it has the advantage of
being based on what matters to patients, which is progression. 
The PIB-PET biomarker results represent Abeta amyloid deposition in the brain. We looked at at the relation between 11C-
PIB ligand binding in the brain and: i) conversion from MCI to ADD; or ii) conversion from MCI to other forms of dementia.
Target condition being diagnosed
In this review there are two target conditions: i) Alzheimer's disease dementia (ADD); and ii) other forms of dementia, which
are assessed at follow-up.
We compared the index test results obtained at baseline with the results of the reference standards obtained at follow-up
(delayed verification). 
Index test(s)
The 11C-PIB-PET scan is an index test for the detection of Abeta deposition in the brain region of interest (ROI). The ROI is
a selected brain area that physicians create for futher study, in various anatomical areas of the brain.
11C-PIB is a molecular biomarker, a N-methyl-[11C]2-(4ʹ-methylaminophenyl)-6-hydroxybenzothyazole radiotracer
derived from thioflavin T (Klunk 2004). Price 2005 fully evaluated quantitative 11C-PIB-PET data in order to identify a valid,
simple and reliable PET quantisation method for the routine measure of brain amyloid retention in vivo.
Criteria for 11C-PIB-PET positivity: there are currently no generally accepted standards for 11C-PIB threshold, and
therefore it was not possible to pre-specify it. We planned to use the criteria that were applied in each included primary
study to classify participants as either test positive or test negative. Positivity is a 11C-PIB-PET uptake and retention
exceeding a certain threshold.
Measure of 11C-PIB amyloid retention (retention ratio): distribution volume ratio (DVR), standardized uptake value ratio
(SUVR), or other ratios will be considered. DVR refers to the ratio of the 11C-PIB ligand distribution volume in the selected
area (ROI) to the distribution volume in the reference area (usually cerebellum). SUVR is the measured activity in the ROI,
which is normalised for body weight, surface area, and injected dose.
Image analysis: not pre-specified (e.g. Statistical Parametric Mapping (SPM), MilxView medical image, and analysis
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software or other image analysis techniques).
Time between 11C-PIB injection and PET acquisition: not pre-specified (e.g. 40 minutes, 60 minutes, 50 to 70 minutes, 90
minutes).
11C-PIB injection dose: not pre-specified (e.g. 300 MBq, 370 MBq).
11C-PIB retention detecting regions: not pre-specified ROI (e.g. global cortex, thalamus, frontal, parietal, temporal cortices
or posterior cingulum, or a combination of these) (e.g. global cortex, caudate nucleus, putamen, thalamus, pons, etc.).
Although it is inevitable for included studies to use different imaging protocols and varied parameters, the amyloid PET data
in these included studies should be technically adequate and should be acquired at a fully qualified and certified facility. The
protocol for the qualitative read that determines positivity or negativity should be be standardized and should conform to a
specific guideline.
Clinical Pathway 
Dementia develops over several years. There is a presumed period when people are asymptomatic but when pathology is
accumulating. Individuals or their relatives may then notice subtle impairments of recent memory. Gradually more cognitive
domains become involved and difficulty in planning complex tasks becomes increasingly apparent. In the UK, people usually
present to their general practitioner, who may administer cognitive tests and refer the person to a hospital memory
clinic. However, many people with dementia do not present until much later in the disorder and will follow a different pathway
to diagnosis, for example being identified during an admission to a general hospital for a physical illness. Thus the pathway
influences the accuracy of the diagnostic test. The accuracy of the test will vary with the experience of the administrator, and
the accuracy of the subsequent diagnosis will vary with the history of referrals to the particular healthcare setting. Diagnostic
assessment pathways may vary in other countries and diagnoses may be made by a variety of specialists including
neurologists and geriatricians. We anticipated that the main way in which 11C-PIB-PET scans will be used is as an additive
test to clinical signs and other tests.
Alternative test(s)
Alternative tests are not included in this review because there are currently no standard practice tests available for the
diagnosis of dementia. The Cochrane Dementia and Cognitive Improvement Group (CDCIG) is in the process of conducting
a series of diagnostic test accuracy reviews of biomarkers and scales (see list below). Although we are conducting reviews
on individual tests compared to a reference standard, we plan to compare our results in an overview.
18F-FDG-PET (18F-2-fluoro-2-deoxy-D-glucose).
Cerebrospinal fluid (CSF) analysis of Abeta and tau.
Structural magnetic resonance imaging (sMRI).
Neuropsychological tests (Mini-Mental State Examination (MMSE); MiniCOG; Montreal Cognitive Assessment (MoCA)).
Informant interviews (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); AD8).
ApoE4.
Fluoropropil-carbomethoxy-iodophenil-tropane single-photon emission tomography (FP-CIT SPECT).
Rationale
The new diagnostic criteria for Alzheimer’s disease and MCI due to Alzheimer’s disease ( Dubois 2010; Albert 2011; 
McKhann 2011; Sperling 2011) incorporate add-on biomarkers based on imaging or CSF measures. These tests added on
to core clinical criteria might increase the sensitivity or specificity of a testing strategy.
The 11C-PIB-PET scan might facilitate accurate identification of those patients with MCI who would convert to
Alzheimer’s disease or other forms of dementia. At the present time there is no 'cure' for dementia, but there are some
treatments which can slow cognitive and functional decline, or reduce the associated behavioural and psychiatric
symptoms of dementia (Birks 2006; McShane 2006). In addition, the accurate early diagnosis of dementia may improve
opportunities for the use of newly-evolving interventions designed to delay or prevent progression to more debilitating
stages of dementia (Oddo 2004).
The disappointing clinical trial result for Alzheimer's disease-modifying therapies in people suggests that treatment
should be targeted at earlier stages in the disease, such as MCI (Friedrich 2014). Abeta biomarkers such as PIB-PET
imaging may be essential to allow for testing an Abeta immunotherapy drug on MCI patients with evidence of brain
Abeta pathology, and seem to be useful in assessing the effects of pre-dementia phase preventive treatments of
potential Alzheimer's disease on cortical fibrillar Abeta load in vivo (Rinne 2010; Blennow 2014; Salloway 2014).
It is crucial that the 11C-PIB-PET scan is assessed for its diagnostic accuracy in patients with MCI before being adopted as a
routine add-on test in clinical practice.
Objectives 
To determine the diagnostic accuracy of the 11C- PIB-PET scan as the index test for detecting participants with mild
cognitive impairment (MCI) at baseline who would clinically convert to Alzheimer’s disease dementia (ADD) or other forms
of dementia at follow-up.
Secondary objectives
To investigate the heterogeneity of the test accuracy in the included studies.
Methods 
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Criteria for considering studies for this review
Types of studies 
We considered longitudinal studies that had prospectively defined cohorts with any accepted definition of MCI with baseline
11C-PIB-PET scan and the reference standard results obtained at follow-up (see Index tests and Reference standards
below). These studies necessarily employ delayed verification of conversion to dementia and are sometimes
labelled as 'delayed verification cross-sectional studies' (Knotnerus 2002; Bossuyt 2008). 
We included case control studies when they incorporated a delayed verification design. This occurred in the context of a
cohort study, so these studies are invariably diagnostic nested case-control studies.
Participants
Participants recruited and clinically classified as those with MCI at baseline were eligible for this review. The
diagnosis of MCI was established using the Petersen criteria or revised Petersen criteria (Petersen 1999; Petersen 2004; 
Winblad 2004), the Matthews 2008 criteria, or CDR = 0.5 (Morris 1993), or a combination. These criteria include: subjective
complaints; a decline in memory objectively verified by neuropsychological testing in combination with a history from the
patient; a decline in other cognitive domains; no or minimal impairment of activities of daily living; not meeting the criteria for
dementia. Therefore, the eligible participants had a number of tests, for example neuropsychological tests for cognitive deficit
and checklists for activities of daily living, prior to study entry. Participants in some studies were defined as amnestic single
domain, amnestic multiple domain, non-amnestic single domain, non-amnestic multiple domain, or non-specified MCI
participants. We considered these studies for inclusion. We also considered studies without reference to a particular source
of recruitment (participant setting) for inclusion.
We excluded studies that involved patients with MCI possibly caused by: i) current or a history of alcohol or drug abuse; ii)
central nervous system (CNS) trauma (for example subdural haematoma), tumour, or infection; iii) other neurological
conditions (for example Parkinson’s or Huntington’s diseases).
Index tests
11C-PIB-PET imaging test
We used the criteria that were applied in each included primary study to classify participants as either 11C-PIB positive or
11C-PIB negative. We considered positivity as 11C-PIB ligand uptake and retention exceeding a certain threshold.
Target conditions
There were two target conditions in this review:
Alzheimer’s disease dementia (ADD) (conversion from MCI to ADD);1.
Any other forms of dementia (conversion from MCI to any other forms of dementia).2.
Reference standards
The reference standard was progression to the target conditions. For the purpose of this review, several definitions
of ADD were acceptable. Included studies applied probable or possible National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (now known
as the Alzheimer's Association) (NINCDS-ADRDA) criteria (McKhann 1984). The Diagnostic and Statistical Manual of
Mental Disorders (DSM) (DSMIII 1987; DSMIV 1994) and International Classification of Diseases (ICD) (World Health
Organization 2010) definitions for ADD were also acceptable.
Similarly, differing clinical definitions of other dementias were acceptable. For Lewy body dementia the reference
standard is the McKeith criteria (McKeith 1996; McKeith 2005); for frontotemporal dementia (FTD) the Lund criteria (Neary
1988; Brun 1994; Boxer 2005), DSM (DSMIII 1987; DSMIV 1994), ICD (World Health Organization 2010); and for
vascular dementia the National Institute of Neurological Disorders and Stroke and Association Internationale pour la
Recherché et l'Enseignement en Neurosciences (NINDS ARIEN) criteria (Roman 1993), DSM (DSMIII 1987; DSMIV 1994
), and ICD (World Health Organization 2010).
The time interval over which progression from MCI to ADD or other forms of dementia occurred is very important. We chose
one year as the minimum period of delay in the verification of the diagnosis (that is the time between the assessment at
which a diagnosis of MCI is made and the assessment at which the diagnosis of dementia is made). We planned to segment
analyses into separate follow-up mean periods for the delay in verification: one year to less than two years; two to less than
four years; and greater than four years. In this eventuality we planned to clearly note where the same included studies
contributed to the analysis for more than one reference standard follow-up interval.
Search methods for identification of studies 
Electronic searches 
On 12 January 2013 we searched MEDLINE (OvidSP), EMBASE (OvidSP), BIOSIS Previews (ISI Web of Knowledge),
Science Citation Index (ISI Web of Knowledge), PsycINFO (OvidSP), and LILACS (BIREME). See Appendix 1 for details of
the sources searched, the search strategies used, and the number of hits retrieved. No language restriction was applied to
the electronic searches.
Searching other resources 
The reference lists of all relevant studies were checked for additional studies. Searches were also
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conducted in the MEDION database (Meta-analyses van Diagnostisch Onderzoek) (www.mediondatabase.nl
), DARE (Database of Abstracts of Reviews of Effects) (www.york.ac.uk/inst/crd/crddatabases.htm#DARE
), HTA Database (Health Technology Assessments Database) (www.york.ac.uk/inst/crd/crddatabases.htm#HTA
), and ARIF database (Aggressive Research Intelligence Facility) (www.arif.bham.ac.uk) for other related systematic
diagnostic accuracy reviews; and a dataset of systematic reviews of diagnostic studies from the International Federation of
Clinical Chemistry and Laboratory Medicine Committee for Evidence-based Laboratory Medicine database (C-EBLM) was
sought. Reference lists of any relevant systematic reviews were checked for additional studies.
Data collection and analysis 
Selection of studies 
The Cochrane Dementia and Cognitive Impairment Group (CDCIG) Trial Search Co-ordinator, a researcher with experience
of diagnostic test accuracy systematic reviews, performed the first assessment of the search results in order to remove the
obvious non-relevant studies. Two authors independently reviewed the remaining titles and abstracts for potentially eligible
studies for full paper review. Two authors independently assessed the full manuscripts against the inclusion criteria. Where
necessary, a third review author acted as arbitrator to resolve disagreements that the two review authors were not able to
resolve through discussion.
Where a study did not present all relevant data for creating a 2 x 2 table, we contacted the authors directly to request further
information. When the same data set was presented in more than one paper, we included as the primary paper the paper
with the largest number of patients or with the most informative data.
Data extraction and management
We planned to extract the following data on study characteristics if reported.
Bibliographic details of primary paper:
author, title of study, year, and journal.
Basic clinical and demographic details:
number of participants;
clinical diagnosis;
MCI clinical criteria;
age;
gender;
sources of referral;
participant recruitment;
sampling procedures.
Details of the index test:
method of the PIB test administration, including who administered the test;
thresholds used to define positive and negative tests;
other technical aspects as seemed relevant to the review, e.g. brain areas.
Details of the reference standard:
definition of ADD and other dementias used in reference standard;
duration of follow-up from time of index test performed to defining ADD and other dementias by reference standard;
prevalence or proportion of population developing ADD and other dementias, with severity if described.
We created 2 x 2 tables (cross-relating index test results of the reference standards) as shown in Appendix 2.
The numbers lost to follow-up were recorded for each included study.
We also extracted data necessary for the assessment of quality as defined below.
Data extraction was performed independently by two blinded review authors (NS, ZS). Disagreement in data extraction was
resolved by discussion, with the potential to involve a third author (CH) as arbitrator if necessary.
Assessment of methodological quality
We assessed the methodological quality of each study using the QUADAS-2 tool (Whiting 2011) as recommended by The
Cochrane Collaboration. The tool is made up of four domains:
patient selection;
index test;
reference standard;
patient flow. 
Two independent raters (NS, MW), blinded to each other’s scores, performed the QUADAS-2 assessment. Disagreement
was resolved by further review and discussion with the potential to involve a third author (CH) as arbitrator if necessary.
We assessed each domain in terms of risk of bias, with the first three domains also considered in terms of applicability
concerns. The components of each of these domains and a rubric which details how judgements concerning risk of bias
were made are detailed in Appendix 3. Key areas important to quality assessment are participant selection, blinding, and
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missing data.
We did not use QUADAS-2 data to form a summary quality score. We produced a narrative summary describing the
numbers of studies that were found to have high, low, or unclear risk of bias as well as concerns regarding applicability.
Statistical analysis and data synthesis
We evaluated test accuracy according to the target condition. There are no accepted thresholds to define PIB-PET
positivity for ADD and other forms of dementia, and so the estimates of diagnostic accuracy reported in primary
studies were likely to be based on data-driven threshold selection (Leeflang 2008) unless pre-specified. We conducted
exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver
operating characteristic (ROC) space. We meta-analysed pairs of sensitivity and specificity using the hierarchical
summary ROC (HSROC) model (Rutter 2001) that allows for the possibility of variation in threshold between studies. Where
adequate studies were available to estimate all parameters, we assumed a symmetrical shape to the summary ROC curve.
Estimates of summary sensitivities and specificities are not clinically interpretable when studies with mixed thresholds are
included in the HSROC model, and so we derived estimates of sensitivity and likelihood ratios at fixed values (lower quartile,
median, and upper quartile) of specificity from the HSROC models. The analyses were performed using the NLMIXED
procedure in the SAS software (version 9.2; SAS Institute 2011, Cary, NC).
Investigations of heterogeneity
We planned to investigate the effects of the following factors.
Spectrum of patients (mean age, gender, MMSE score, APOE ε4 status). For age, we planned to separately examine any
study that included 30% of patients below the age of 65 years.
Referral centres: primary care, memory clinic, and hospital.
Clinical criteria of MCI: Petersen criteria, revised Petersen criteria, CDR = 0.5 criteria, and different MCI
classification (Matthews 2008).
11C-PIB retention ratio.
Image analysis techniques.
Time between 11C-PIB injection and PET acquisition.
11C-PIB injection dose.
11C-PIB retention detecting regions.
Reference standard(s) used: NINCDS-ADRDA, DSM, and ICD 10 for ADD.
Duration of follow-up: 1 year to < 2 years, 2 to < 4 years, and > 4 years.
Aspects of study quality, particularly inadequate blinding and loss to follow-up: we considered separately those studies
that had more than 20% dropouts.
Conflict of interest.
In preliminary analyses, we visually examined forest plots of sensitivity and specificity, and summary ROC plots to explore
the effect of each of these factors. If there were sufficient studies, we planned to perform meta-regression by including each
potential source of heterogeneity as a covariate in the HSROC model.
Sensitivity analyses
We investigated the effect of pre-specification of threshold and PIB positivity on diagnostic accuracy by performing sensitivity
analyses.
Assessment of reporting bias
We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the
interpretation of existing analytical tools such as funnel plots.
Results 
Results of the search
The total number of records identified by the searches for this review was 14,951. After de-duplication, a small team of
assessors performed a first-assess on the remaining records. The PRISMA diagram (Figure 1) shows the flow of studies
through the screening and selection processes. In total, 103 studies (94 full text papers and 11 conference publications)
were assessed for eligibility. We included nine studies and one was identified as an ongoing study. We excluded 93 studies.
Nineteen studies were multiple publications and 11 did not have extractable data for constructing 2 x 2 tables (see
Characteristics of excluded studies). The remaining 63 studies were excluded as they did not meet the inclusion
criteria: i) not MCI participants at baseline (n = 10); ii) not a delayed verification study (n = 40); iii) index test not PIB-
PET scan (n = 1); iv) discussion papers (n = 3); and v) conference publications and no reply when authors were
contacted (n = 9) (Okello 2007; Ellis 2011; Maruff 2011; Perrotin 2011; Rentz 2011; Villain 2011; Villemagne 2011a; 
Hatashita 2012; Mosconi 2012). No extra studies were found through reference checking. Usable data were obtained for
three studies (Jack 2010; Ossenkoppele 2012; Ossenkoppele 2012a) by contacting the authors of the studies.
Included studies
The Characteristics of included studies table lists the characteristics of the nine included studies containing a total of 300
participants with MCI at baseline.
Of the 274 participants with analysable data, 112 developed Alzheimer’s dementia and nine non-Alzheimer's
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dementia. The remaining 26 participants were reported to be lost to follow-up. The majority (n = 18) of
participants were missing from a single study (Ossenkoppele 2012a). All the studies were published in recent years (2009 to
2013). Most of them (6/9) were conducted in Europe (two in the Netherlands, one in the UK and Finland, one in Finland
alone, one in Sweden, one in Germany); two in the USA; and one in Australia. All included studies used one version or
another of the Petersen criteria for MCI. Eight studies applied NINCDS-ADRDA criteria as a reference standard for ADD;
Koivunen 2011 also used DSM-IV criteria; Ossenkoppele 2012a did not explicitly state what reference standard was used at
follow-up.
Demographic and patient characteristics are summarised in Table 1. Study sizes were small and ranged from 15 to 67.
Four papers reported a mean age of over 70 years (Jack 2010; Koivunen 2011; Villemagne 2011; Wolk 2009) while
five papers reported a mean age below 70 years (Okello 2009; Forsberg 2010; Ossenkoppele 2012; Ossenkoppele 2012a; 
Grimmer 2013). The youngest study population was aged 64 ± 9 years (Ossenkoppele 2012a) and the oldest
study population was aged 73.4 ± 8.5 years (Villemagne 2011). Gender, APOE Ɛ4 carriers, years of education, and
sampling procedure were poorly reported. Participants were mainly recruited from secondary care (five studies from
outpatient clinics and one study from inpatient department), one study recruited the participants from a tertiary setting (Wolk
2009), one from a mixed setting (Jack 2010), and one did not report the sources of recruitment (Ossenkoppele 2012).
Table 2 and Table 3 summarise the data regarding the threshold used, the measure of PIB amyloid retention,
image analysis, PIB dose and the time between PIB injection and performing a PET scan, and PIB retention
detecting region of interest (ROI). The studies applied different analytic approaches to PET data, ranging from
quantitative binding potentials (BPs) or distribution volume ratios (DVRs) using invasive arterial sampling to
semi-quantitative standardized uptake value ratios (SUVR). Seven studies used seven different thresholds
and two studies did not report the threshold used. Six different measures were used for PIB retention and six
different ROIs were investigated for detecting PIB retention in nine included studies. The timing of the scans
and data acquisition (dynamic versus static) also varied greatly across studies. Duration of follow-up was
reported as the mean and SD, median, or maximum duration, or it was not reported at all. Duration of follow-
up varied substantially but was mostly within the 18 to 36 months range. PIB positivity ranged from 42% (Ossenkoppele
2012) to 72% (Koivunen 2011). Conversion to ADD ranged from 22% (Wolk 2009) to 59% (Koivunen 2011). The included
studies varied markedly in how the PIB scans were done and interpreted.
Excluded studies
Eleven studies were excluded as they failed on the inclusion criteria for participants, index test, or target
condition (Characteristics of excluded studies).
Methodological quality of included studies
Methodological quality was assessed using the QUADAS 2 tool (Whiting 2011). Review authors’ judgements about each
methodological quality item for each included study are presented in the Characteristics of included studies table and Figure
2. The overall methodological quality of the studies is summarised in Figure 3.
In the patient selection domain, we considered seven studies (78%) to be at unclear risk of bias due to poor reporting on
sampling procedures and exclusion criteria. We stated that all included studies avoided a case-control design because
we only considered data on performance of the index test to discriminate between patients with MCI who converted to
dementia and those who remained stable. We considered two remaining studies to be at high (Jack 2010) and low
(Koivunen 2011) risk of bias because the participants were not systematically enrolled or were consecutively or randomly
enrolled, respectively.
In the index test domain, we considered six studies (67%) at low risk of bias because the threshold used was pre-
specified and the index test results were interpreted without knowledge of the results of the reference standard. We
considered two studies (Forsberg 2010; Ossenkoppele 2012a) to be at high risk of bias because the threshold used was not
pre-specified and the optimal cut-off level was determined from ROC analyses; therefore, the accuracy of the 11
C-PIB biomarker that was reported in these studies appeared to be overestimated. We considered the
remaining one study (Ossenkoppele 2012) to be at unclear risk of bias due to poor reporting.
In the reference standard domain, we considered five studies (55%) to be at unclear risk of bias because it was not reported
whether the clinicians conducting follow-up were aware of the initial 11C-PIB biomarker analysis results. We were not
able to obtain the information about how the reference standard was obtained and by whom due to poor reporting. We
considered three studies to be at high risk of bias (Wolk 2009; Ossenkoppele 2012; Ossenkoppele 2012a) and one
study (Grimmer 2013) to be at low risk of bias.
In the flow and timing domain, we judged eight studies (89%) to be of low concern for risk of bias because all patients were
accounted for in the analysis or the reasons for missing data were given, and the time interval between the index test and
reference standard was appropriate (duration of follow-up was longer than one year). Shorter durations of follow-up may
yield low conversion rates and this might have an effect on the diagnostic accuracy of the index test; therefore, these scores
might be overstated and should be interpreted with caution. We considered one remaining study (Ossenkoppele 2012a) to
be at high risk of bias because a large number of patients were excluded from the analyses.
For assessment of applicability, there was no concern that the included patients and setting, the conduct and interpretation of
the index test, and the target condition (as defined by the reference standard) in each of the included studies did not match
the review question.
It should be noted that the lack of concern about the applicability of the three domains mentioned above was based on
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the inclusion criteria that were set for the review. Considering the level of heterogeneity with respect to the nature of the
index test (Table 2; Table 3), it appeared that the judgement about applicability may be overstated.
Findings
The key characteristics of each study are summarised in Table 1 and Table 2. The summary of main results for nine included
studies is presented in the Summary of findings table 1.
11C-PIB-PET for Alzheimer's disease dementia (ADD)
Individual study estimates of sensitivity and specificity, and the threshold used to define test positivity, are shown in Figure 4
for each of the nine studies (112 cases and 162 non-cases) that evaluated ADD. The sensitivities were between 83% and
100% while the specificities were between 46% and 88%. The criteria for 11C-PIB positivity varied between studies: five
studies used a quantitative threshold while the remaining four studies used visual inspection. The nine studies used different
measures of 11C-PIB amyloid retention (ROI to cerebellar ratio, average neocortical to cerebellar ratio, posterior cingulate
to cerebellar ratio, or visual inspection of parametric nondisplaceable binding potential (BPND) images or SUVR images). The
mode of image analysis also varied between studies.
The summary ROC curve summarising the accuracy of PIB-PET across the nine studies is shown in Figure 5. Because of
the variation in thresholds and measures of 11C-PIB amyloid retention, we did not estimate summary sensitivity and
specificity. However, we derived estimates of sensitivity and likelihood ratios at fixed values of specificity (see Table 4) from
the model we fitted to produce a summary ROC curve. At the median specificity of 58%, the estimated sensitivity was 96%
(95% CI 87 to 99), the positive likelihood ratio was 2.29 (95% CI 2.17 to 2.41), and the negative likelihood ratio was 0.07
(95% CI 0.02 to 0.24).
11C-PIB-PET for all types of dementia (combined Alzheimer's disease and non-ADD)
Four studies (59 cases and 58 non-cases) evaluated the accuracy of PIB-PET for all types of dementia (Figure 6) in addition
to evaluating ADDa. The sensitivities were between 75% and 86% while the specificities were between 50% and 86%. Two
studies used a quantitative threshold while the other two used visual inspection to determine test positivity. Meta-analysis
was not performed because the studies were few and small, and there was considerable heterogeneity. Figure 7 shows
study specific estimates of sensitivity and specificity in the ROC space together with their 95% CIs.
Investigation of heterogeneity
The planned investigations were not possible due to the limited number of studies available for each analysis. For type of
reference standard, seven of the nine studies used NINCDS-ADRDA. Therefore, we conducted sensitivity analyses
restricting the analysis to only studies that used NINCDS-ADRDA as the reference standard.
Sensitivity analyses
Due to the limited number of studies evaluating 11C-PIB-PET for all dementia, we performed sensitivity analyses only for
studies of ADD.
Type of reference standard
Of the nine studies that evaluated 11C-PIB-PET for ADD, seven used NINCDS-ADRDA as the reference standard.
To explore the impact of type of reference standard on the summary estimates, we excluded one study (Koivunen 2011
) that used NINCDS-ADRDA and DSM IV as the reference standard and another study (Ossenkoppele 2012a) where
the reference standard used was unclear. There was no impact on our findings (Table 4).
Threshold pre-specified
Seven studies pre-specified thresholds for test positivity. The two studies that did not pre-specify the threshold (Forsberg
2010) or did not report whether or not thresholds were pre-specified (Ossenkoppele 2012) were excluded in this
analysis. There was no impact on our findings (Table 4).
Discussion 
Summary of main results
The volume and quality of evidence on the diagnostic accuracy of 11C-PIB-PET for early diagnosis of ADD and other
dementias in patients with MCI was limited. The results are summarised in Summary of findings table 1. Due to variations in
thresholds and the measurement of 11C-PIB amyloid retention, we estimated a summary ROC curve for studies that
evaluated conversion from MCI to AD dementia; we did not estimate a summary sensitivity and specificity on the curve
because with mixed thresholds a summary point lacks a clnically meaningful interpretation. At the median specificity of 58%
the estimated sensitivity of 11C-PIB-PET for identifying patients with MCI that will convert to AD, derived from the summary
ROC curve, was 96% (95% CI 87% to 99%).
Data were not pooled for the four studies that evaluated conversion from MCI to all types of dementia; the sensitivities were
between 75% and 86%, and the specificities were between 50% and 86%.
11C-PIB-PET for Alzheimer's disease dementia (ADD)
PIB had high sensitivity for predicting conversion to Alzheimer's disease but poor specificity. In other words, the high
false positive rate suggested that amyloid imaging was not only an imaging biomarker for Alzheimer's disease but
perhaps also for other neurodegenerative diseases and 'asymptomatic' neurological disease, even in healthy people (Chen
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2014). It has been demonstrated that PIB binds to amyloid in vessel walls (Bacskai 2007; Johnson 2007), in particular to
cerebral amyloid angiopathy. Therefore, vascular Abeta could be another major contributor to the in vivo PIB signal.
A recent study (Ducharme 2013) reported that a patient met clinical criteria for probable Alzheimer's DD but had a higher
than expected burden of white matter disease on magnetic resonance imaging (MRI). A 11C-PIB-PET scan was
highly positive in typical Alzheimer's disease distribution. Six months after the assessment the patient died of an
intracerebral haemorrhage and an autopsy revealed cerebral amyloid angiopathy (CAA) in the complete absence of
amyloid plaques or neurofibrillary tangles (NFT). So it is suggested that an uncertain percentage of cognitively
normal individuals or with clinical MCI who have positive amyloid PET imaging (Sperling 2011) in fact could have CAA rather
than AD. On the other hand, we did not estimate a summary specificity and so far there is no large-scale 11C-PIB-PET study
with MCI pathology, therefore it is unknown whether there are 'false positives' that may in fact be vascular MCI due to CAA in
some of the included studies. We would also speculate that the final pathological diagnosis of some patients with clinical
probable AD may be vascular dementia secondary to CAA.
11C-PIB-PET may not be able to detect more soluble species of Abeta-42 or other atypical amyloid deposits (Leinonen 2008
) thus producing false negative results. This is rare, however, and it is more likely that these patients present with an
AD-like phenotype that originates from non-amyloidogenic neuropathology. Indeed, multiple contradictory PIB binding
results in humans have been reported and a study demonstrating that PIB brain accumulation may be at least in part
mediated by PIB sulfation via estrogen sulfotransferase (Cole 2010) has cast doubts on the purported human amyloid
specificity of PIB. This phenomenon emphasizes the potential that there might be types of Abeta deposits that PIB does
not detect (Shin 2011). Another study (Shin 2010) demonstrated that NFTs, rather than amyloid plaques, were
predominantly accumulated in the hippocampal formation in some patients with ADD. PIB can only be bound to
senile plaques specifically, but not tangles, sp we can speculate that NFTs might be more pronounced or have
happened earlier than amyloid plaques in some PIB negative MCI converters. The notion about NFT pathology has
been further strengthened by some neuropathologic studies with autopsy data from ADD. The data from cohort
research (Serrano-Pozo 2013) indicated that plaques and tangles independently contribute to cognitive impairment in
AD pathology without any other primary neuropathologic diagnosis. Furthermore, NFT formation must be either
unrelated to amyloid plaques formation or a temporally distinct process, or both. (Royall 2014).
Another hypothesis that can explain false negative results is that those with probable ADD may have multiple brain
pathologies, most commonly AD with macroscopic infarcts, followed by AD with neocortical Lewy body disease.
Similar to AD, the pathology underlying MCI is heterogeneous (Schneider 2007; Schneider 2009). Until now, it is unknown
whether the complicated and mixed pathology can have an effect on imaging and diagnosis with 11C-PIB-PET, but we
speculate that mixed neuropathology of probable Alzheimer's disease and MCI may play a role in PIB negative MCI
converters.
Duration of follow-up is also important in predicting conversion to ADD. Although the mean, median, or maximum
follow-up period of the included studies was more than one year, the variability in the duration of follow-up was
considerable. The reported conversion rate of MCI to AD is between 8% and 16% per year (Mitchell 2009), and the
cumulative conversion rate ranged from 22% to 69%, but unfortunately we were not able to calculate conversion rate per
year of each of the included studies because of insufficient data. Conversion rates of MCI could have influenced the test
results in our review. We took it for granted that given a long follow-up period, a high percentage of patients with baseline
MCI would progress to Alzheimer's disease thus affecting the predictive accuracy of 11C-PIB-PET. However, there was not a
positive correlation between follow-up time and percentage of conversions. For example, the cumulative conversion rate of
MCI in Villemagne 2011 was 68.9%, which was the highest among these included studies, but the maximum follow-up period
did not exceed two years in this study. The range of follow-up in Ossenkoppele 2012 was from two to four years,
whereas the corresponding cumulative conversion rate did not exceed 34% (Table 2). The differences are significant among
these studies. As a consequence, we were not able to investigate the effect of duration of follow-up on the conversion rate
due to a high level of heterogeneity and the small number of included studies.
The length of follow-up duration also may have a direct effect on diagnostic accuracy for progression of MCI to dementia. So
far the results of the longest follow-up study with two times for 11C-PIB-PET scans (two and five years),
conducted by Kemppainen (Kemppainen 2014) and only including 10 MCI participants, were consistent with a 100%
specificity of a positive 11C-PIB-PET scan for predicting five year MCI to Alzheimer's disease conversion. This differs from
our review, which reports 46% to 88% specificity of PIB PET for predicting one to four 4 year conversion. Furthermore, the
estimated 75% sensitivity of baseline 11C-PIB PET scans for predicting MCI to Alzheimer's disease conversion in
Kemppainen 2014 is in turn lower than the reported 83% to 100% sensitivity in our review. The inconsistent estimates might
be explained by the longer duration of the follow-up period. Additionally, only one MCI participant was diagnosed with
Alzheimer's disease at the time of the two year scan, while the others converted between the two year and five year scans.
The interval between the two scans and inconsistent accuracy thus reflect the fact that a complete understanding of the role
of 11C-PIB-PET in the prediction of decline in MCI will not only require both short and long-term periods of observation but
will also need to clarify inter-individual variation in the cerebral amyloid load in MCI, and in the course of amyloid
accumulation in relation to the clinical diagnosis of disorders associated with cognitive impairment.
Some demographic and MCI characteristics may be other underlying factors that can increase the conversion rate.
More and more attention has been paid to the relationship between MCI subtypes and conversion to dementia. The
largest ever longitudinal study, with results from the follow-up of 550 MCI patients, indicated that the MCI subtype,
presence of storage memory impairment, multiple domain condition, and presence of APOE ε4 allele increased the
risk of conversion to dementia. Multivariate survival and Kaplan-Meier analyses showed that amnestic MCI with
storage memory impairment had the most and closest risk of conversion to dementia (Espinosa 2013). In our review the
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only longitudinal study with MCI subtypes (Wolk 2009) found that both amnestic MCI and non-amnestic MCI subtype
were associated with a significant proportion of amyloid positive scans and, in particular, there were no obvious
differences in the distribution of PIB retention between the two groups (Wolk 2009). None of the included studies had
analysed the underlying correlation or relationship between 11C-PIB-PET imaging with conversion rate and clinical
classification of MCI. In addition, some 'high risk factors' such as positive family history of dementia, presence of Abeta and
tau protein in cerebrospinal fluid, and the APOE ε4 allele may also contribute to a faster conversion rate to dementia.
Although some studies had reported the status of 'risk factors' of MCI at baseline, these were not fully described to include in
the meta-regression. In conclusion, further updated reviews that include high quality research and can provide more detailed
data about the characteristics of MCI are required to not only explore the underlying mechanisms but also to elucidate the
causal pathways that link PIB positivity of diverse MCI subtypes and disease progression.
11C-PIB-PET for any other forms of dementia (non-Alzheimer's disease dementia (non-ADD))
We were not able to evaluate the accuracy of the index test for conversion from MCI to non-ADD. Only four
included studies (Villemagne 2011; Ossenkoppele 2012; Ossenkoppele 2012a; Grimmer 2013) reported a small number
(nine) of converters to non-ADD. As a result of the information available from these four studies, we evaluated the target
condition 11C-PIB-PET for all types of dementia (combined Alzheimer's disease and non-ADD) (Figure 6; Figure 7).
11C-PIB-PET positive scans are regularly observed in patients with non-ADD and patients with MCI who progress
to non-ADD, especially FTD and dementia with Lewy bodies (DLB) (Rabinovici 2011; Albin 2013).
Both DLB and Parkinson’s disease dementia (PDD) are characterised at autopsy by the presence of subcortical or
cortical Lewy bodies, or both. Patients with DLB frequently have levels of PIB uptake above that of controls and
occasionally equivalent to Alzheimer's disease (Rowe 2007). Most studies have found higher amyloid plaques in DLB
than in PDD or non-demented Parkinson’s disease patients, and in some studies PIB positivity was associated with
greater cognitive deficits and more rapid disease progression (Foster 2010). Shimada et al (Shimada 2013) reported
that amyloid deposits are associated with AD-like atrophy in patients with DLB and PDD. Patients with DLB have
higher levels of amyloid deposits than patients with PD and PDD. There was one autopsy-based study of a patient
with DLB with a positive PIB scan due to CAA, but the concurrent pathological evidence of amyloid plaques and
NFTs complicated this case (Bacskai 2007), while Lewy bodies themselves contributed little if at all to the overall
PIB-PET signal, and α-synuclein and Aβ-42 increased each other’s toxicity (Masliah 2001). Amyloid deposits have
been linked to cognitive impairment in DLB (Gomperts 2012) and Parkinson's disease without dementia (Gomperts 2013),
which may contribute to the timing of the onset of dementia relative to that of Parkinsonism in DLB.
Frontotemporal lobe degeneration (FTLD) is an umbrella term used for disorders associated with neurodegeneration of the
frontal and anterior temporal lobes. Clinical syndromes that are in the FTLD spectrum include the behavioural variant of
frontotemporal dementia (bvFTD), semantic dementia (SD), and progressive non-fluent aphasia (PNFA). A study of PIB
retention in patients with FTD reported that most patients with FTD displayed no PIB retention and that 11C-PIB-PET
could potentially aid in differentiating FTD and Alzheimer's disease (Engler 2008). However, FTD cases have
occasionally demonstrated PIB positive scans and it remains unclear whether these cases represent mixed FTLD
and Alzheimer's disease, Alzheimer's disease manifesting clinically as FTD, or false-positive cases of FTD (Rabinovici
2007), which may suggest the mimicking of Alzheimer's disease pathology; SD and PNFA are less likely to
demonstrate PIB uptake, and it is known from postmortem studies that about 15% to 20% of clinical FTD patients
actually have Alzheimer's disease (Forman 2006). Four out of nine included studies (Villemagne 2011; Ossenkoppele 2012; 
Ossenkoppele 2012a; Grimmer 2013) reported that five MCI participants converted to FTD during the course of the study. All
five 11C-PIB-PET scans of those with MCI were negative suggesting the test is insufficient to evaluate the early diagnostic
value for progression from MCI to FTD.
Data for all types of dementia are limited in this systematic review. Although high PIB retention is common in MCI and is a
powerful predictor of subsequent conversion to Alzheimer's disease, the current available data suggest that PIB may play a
similar role in all dementia; at baseline, imaging Abeta may seem bland but deleterious effects emerge as patients with MCI
decline cognitively over time to dementia.
Strengths and weaknesses of the review
Our review was planned and conducted following the criteria and methods set out in our published protocol. Our
searches were comprehensive and sensitive. We used major electronic databases and wide search terms, and also
checked the reference lists of systematic review databases for additional studies. Our searches were not limited by
language. We contacted study authors and usable data were obtained for three studies (Jack 2010; Ossenkoppele 2012; 
Ossenkoppele 2012a). Our methodological quality assessment and data syntheses were based on recommended methods.
To increase the reliability of our findings, we included only studies that fulfilled delayed verification of conversion to dementia.
Our review has some limitations. The clinical diagnosis of ADD or other forms of dementia is imperfect, therefore the findings
from studies with postmortem confirmation of the diagnosis are more convincing than those from studies with clinical
diagnosis in the evaluation of the accuracy of PET imaging in the early detection of the dementia process in MCI.
Considerable attention should be paid to risk stratification of MCI participants (Holland 2012). The stratification of biomarker
and risk factors could enable potentially informative MCI subgroup analyses to emerge, which is helpful for 11C-PIB-
PET to detect the progression in MCI. Besides amyloid positive imaging, several predisposing factors have been
recognized such as FDG-PET hypometabolism, cognitive task-associated changes in functional MRI, abnormality in
structural MRI, presence of APOE ε4 allele, MCI subtypes, age and abnormal cerebrospinal fluid findings that conferred
increased risk for progression to dementia in MCI participants. Most included studies provided some raw data on MCI at
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baseline, nevertheless there are still not enough details reported by included studies for stratifying MCI individuals
based on risk factors. For instance, only one study (Wolk 2009) performed the MCI subtypes analysis. A clear
classification and stratification of MCI may reduce a potential bias in the procedure of patient sampling (Hampel 2012). As a
result of poorly standardized MCI, we suggest that international collaboration should introduce a standardization grading
scale or system, with or without 11C-PIB-PET, to more accurately reflect the conversion risk for 'various types' of MCI.
Applicability of findings to the review question
There was no applicability concern that the included patients and setting, the conduct and interpretation of the index test,
and the target condition (as defined by the reference standard) in each of the included studies did not match the review
question: Could the 11C-PIB biomarker identify those MCI participants with Alzheimer’s disease pathology at baseline who
would convert clinically to dementia at follow up? However, due to the limited number of included studies and levels of
heterogeneity with respect to the three domains mentioned above, it was difficult to determine to what extent the findings
from this meta-analysis could be applied to clinical practice.
The diagnostic utility of 11C-PIB-PET scans for identifying Alzheimer's disease pathology and identifying those patients with
MCI who would convert to ADD could be affected by a number of factors that have not been determined so far. First, PIB
binds to both plaques and cerebral amyloid angiopathy, and the relative contribution of each to the in vivo signal is unknown.
Second, it is not yet clear whether the 11C-PIB-PET scan should be interpreted as a dichotomous test (that is positive versus
negative) or whether the degree and spatial distribution of binding offer additional diagnostic information. Third, it has not yet
been established whether the 11C-PIB threshold should be adjusted based on demographic factors such as age, education,
or genetic variables such as the ApoE ε4 genotype, although the relationship between amyloid and dementia is significantly
weaker in older versus younger individuals.
The 11C-PIB-PET biomarker is a high cost investigation, therefore it is important to clearly demonstrate its accuracy prior to
recommending its adoption in clinical practice.
Authors' conclusions 
Implications for practice 
At present, a 11C-PIB-PET scan is not indicated in patients with MCI except in clinical trials and research studies (Albert
2011). However, the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the
Alzheimer’s Association have proposed the usage of amyloid PET in patients with persistent or progressive
unexplained MCI (Johnson 2013). The diagnostic accuracy of a 11C-PIB-PET scan as determined in this review suggests
that the diagnostic modality has been expected to be a potentially valuable technique for prediction of progression in people
with MCI and the detection method used in clinical practice in the near future.
However, given the heterogeneity in the conduct and interpretation of the test, the lack of defined thresholds for
determination of test positivity and the inconsistency of length of follow-up, we cannot recommend the routine use of 11
C-PIB-PET in clinical practice. The11C-PIB-PET biomarker is a high cost investigation, therefore it is important to clearly
demonstrate its accuracy and to standardize the process for the 11C-PIB diagnostic modality prior to it being widely used.
Implications for research 
Although the National Institute on Aging and the Alzheimer’s Association workgroup had recommended that the diagnostic
criteria for MCI due to Alzheimer's disease in research settings and clinical trials should incorporate the use of biomarkers
based on imaging, such as 11C-PIB-PET (Albert 2011), there is a lack of a generally accepted standardization process and
diagnostic criteria for 11C-PIB-PET for detecting the amyloid image in participants with MCI. We recommend better
standardization of image analysis, the threshold, and other 11C-PIB-PET parameters in research studies. Moreover, the
procedure for acquisition and analysis of the sample need to be established to implement 11C-PIB-PET criteria on a broad
scale. Although we consider biomarkers as 'negative' or 'positive' for the purposes of classification, it is recognized that
varying severities of an abnormality may confer different likelihoods or prognoses, which is currently difficult to quantify
accurately for broad application in research.
Since neurodegenerative diseases are complex disorders with occasionally multiple and overlapping
pathophysiological processes, multitracer imaging may be helpful in combining metabolic, inflammation, or
apoptosis markers with those labelling typical protein aggregations seen in the progression of MCI to
Alzheimer's disease. In future, various PET imaging modalities are needed to evaluate the usefulness of the
various PET tracers as predictors of conversion to Alzheimer's disease in MCI studies with clinical follow-up.
There is a hypothesis that amyloid deposition is an early event in Alzheimer's disease that reaches a relative
plateau even at the MCI stage, while downstream biomarkers measure neuronal loss and dysfunction, and
cognitive measures are more dynamic at the symptomatic disease stage. Based on this hypothesis, the
combination of structural imaging, functional imaging, and cognitive tests may be better predictors of when an
individual will convert. Some studies (Ossenkoppele 2012a; Zhang 2012; Trzepacz 2014) of clinical relevance have
shown that the combination of biomarker modalities, such as PIB-PET, FDG-PET, and structural MR, is likely to provide
the best additional neuroimaging information over that of single imaging. Some comparative studies (Jack 2008; Trzepacz
2014) suggest that structural MRI combined with 11C-PIB-PET produces the highest accuracy for the prediction of
conversion from MCI to Alzheimer's disease and is superior to using either in isolation. Moreover, the combined use of 11C-
PIB and 18F-FDG plus PET provided beneficial information for MCI due to non-ADD (Banzo 2014).
It is worth mentioning the greater consistency in sensitivity as an aspect of the results in our review, suggesting potential
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value of the test as a rule-out test. This needs to be confirmed in larger studies with standardized PIB-PET techniques. We
were not able to fully explore the causes of heterogeneity in specificity, so understanding the variability in specificity (if it
persists when PIB-PET has been standardized) should also be an objective of further research. The above implications
suggest that well designed studies and standardization through international collaboration are required.
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Characteristics of included studies 
Forsberg 2010
Patient Selection
A. Risk of Bias
Patient Sampling
Twenty-one patients with MCI and 37 patients
with mild AD were recruited from Department
of Geriatric Medicine at University Hostpital.
No further details of recruitment were
reported. Participants were referred from the
primary care centres in the community
(Forsberg 2008).
We only included data on performance of the
index test to discriminate between patients
with MCI who convert to dementia and those
who remained stable.
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
21 MCI participants diagnosed by the
modified Petersen criteria (Winblad 2004) at
baseline (Forsberg 2008). All subjects lived
independently in the community and a majority of
the subjects below 65 years of age had still a
professional job
Gender: 8 male; 13 female
AGE: mean: 63.3±7.8 years (range 50–78); MCI-
AD: 63.4±7.9 years; MCI-MCI: 62.6±8.4 years
APOE ε4 carrier: 14 (67%) (8 MCI-MCI; 6 MCI-
AD)
MMSE: mean 28.2±1.4 (range 25–30); MCI-AD
27.0±1.3; MCI-MCI 28.9±0.9
Sources of referral: primary care centres in
community
Setting: secondary care - outpatients
(Department of Geriatric Medicine clinic)
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
The PET examination with 11C-PIB was performed at Uppsala PET centre/Uppsala Imanet AB in
Uppsala, Sweden. Production of 11C-PIB, tracer doses, and scanner protocol for transmissions,
emissions and reconstructions have been described in detail previously (Klunke 2004)
Time between PIB injection and PET acquisition: 60 minutes
PIB administration dose: 300MBq
Quantitative data on 11C-PIB retention were generating giving late scan ratio data for 11C-PIB
retention (Forsberg 2008). ROIs (regions of interest) included the frontal, parietal and temporal
cortices divided right and left, posterior cingulate, striatum, primary visual cortex and thalamus
Threshold: ROI to-cerebellar ratio ＞1.6 (PIB retention detecting regions: global cortex and thalamus).
Threshold determined at follow-up.
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia (conversion from MCI to AD)
Reference standard: NINCDS-ADRDA
criteria
Details of follow-up procedures were not
specified. Unclear whether clinicians
conducting follow-up were aware of PIB-
PET analysis results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
All participants received the same
reference standard
Duration of follow-up: within 8.1±0.5
months (2-16 months) after their PET scans
7 MCI patients converted to AD; after
45.5±8.5 months of clinical follow-up 14
patients remained MCI stable; mean
duration for all participants was not
reported; average: 33.3±19.3 months (the
data was calculated by ZS)
Number included in analysis: 21 MCI: 11
MCI with positive PIB test: 7 converted to
AD and 4 remained stable; 10 MCI with
negative PIB test remained stable
TP=7; FP=4; FN=0; TN=10
Loss to follow-up: data appeared to have
been reported for all 21 participants
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Grimmer 2013
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A. Risk of Bias
Patient Sampling
Participants had been referred for the
diagnostic evaluation by general practitioners,
specialists, or other institutions. No further
details of recruitment were reported
Exclusion criteria: psychotropic medication,
substance misuse, major abnormalities in
routine blood testing, or other neurological or
psychiatric disorders
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
28 MCI participants diagnosed by the
modified Petersen criteria (Winblad 2004)
and CDR=0.5 (Morris 1993) criteria at baseline
Gender: 14 male; 14 female
AGE: mean: 67.9±7.4 years (range 50–79)
APOE ε4 carrier: not reported
MMSE: mean 26.0±3.19 (range 15–30)
Education: 11.8±2.2 years (range 8-17)
Sources of referral: mixed: primary and secondary
care, and other institutions
Setting: secondary care - outpatients (Psychiatry
and Psychotherapy Department clinic)
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
Time between PIB injection and PET acquisition: 40-60 minutes
PIB administration dose: 628 MBq (range 385 to 723 MBq
Threshold: PIB-PET findings at baseline were dichotomised into amyloid positive or amyloid-
negative using a cerebrum to cerebellar vermis ratio threshold of 1.4 as cut-off using proposed
methods described above (Jack 2008).
Threshold determined at baseline.
Index test was conducted at baseline.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia and other forms of dementia
Reference standard: NINCDS-ADRDA
criteria for Alzheimer's disease dementia
and the Land criteria (Brun 1994) for FTD
Clinicians conducting follow-up were
blinded for the baseline PIB-PET findings
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
All participants received the same
reference standard
Duration of follow-up: mean was 31.2±7.8
months
Number included in analysis: 28 MCI: 17
MCI with PIB positive test: 9 converted to
AD and 8 remained stable; 11 MCI with PIB
negative test: 3 converted to non-AD (2
FTD; 1 dementia not specified), 7 remained
stable and 1 reverted to normal
Conversion from MCI to AD dementia:
TP=9; FP=8 FN=0; TN=11
Conversion from MCI to all dementia:
TP=9; FP=8 FN=3; TN=8
Loss to follow-up: data appeared to have
been reported for all 28 participants
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Jack 2010
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A. Risk of Bias
Patient Sampling
218 MCI participants were selected from the
Alzheimer’s Disease Neuroimaging Initiative
(ADNI) (retrospective study). No discussion on
when patients were recruited. 53 participants
assessed by PIB-PET imaging and 165 by
cerebrospinal fluid Aβ42 methods. No sampling
criteria specified.
We only included data on performance of the
PIB-PET index test to discriminate between
patients with MCI who convert to dementia and
those who remained stable at follow-up.
No exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
53 MCI participants diagnosed by the Petersen
2001 criteria. Demographic data reported on
218 participants
Gender: 72 (33%) female
AGE: 75 year
APOE ε4 carrier not reported:
MMSE: median (IQR) 27 (25, 29)
Education: median duration (IQR) 16 (14, 18)
Sources of referral: mixed: the local
Alzheimer’s Disease Research Center
(ADRC), memory clinics, newspaper ads, radio
and other public media campaigns
Setting: mixed (ADNI participants at 13 different
sites)
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
A global cortical PIB PET retention summary was formed by combining the prefrontal, orbitofrontal,
parietal, temporal, anterior cingulate and posterior cingulate/precuneus values for each subject, using
a weighted average of these regions of interest values
Larger regions of interest were given greater weight. PIB PET ratio values calculated by dividing the
median value in each target cortical region of by the median value in the cerebellar grey matter region
of interest of the atlas
Time between PIB injection and PET acquisition: 50-70 minutes
PIB administration dose: not reported
Threshold: mean neocortical distribution volume ratio (DVR) ＞1.5 (PIB retention detecting regions: 
global cortex). Threshold determined at baseline.
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
(conversion from MCI to AD)
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of PIB-PET analysis
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
No discussion on when patients were
recruited
All participants received the same reference
standard
Duration of follow-up: a median progression-
free follow-up time of 1.7 years
Number included in analysis: 53 MCI: 34 MCI
with PIB positive test: 15 converted to AD and
19 remained stable; 19 MCI with PIB negative
test: 3 converted to AD and 16 remained
stable
TP=15; FP=19; FN=3; TN=16
Loss to follow-up: data appeared to have
been reported for all 53 participants
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators contacted; they provided requested data tor the 2X2 table to be
completed; email from Dr Weigand on 11/5/12
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A. Risk of Bias
Patient Sampling
Twenty-nine consecutive MCI patients seen at
the memory clinic and who volunteered for
PET scanning, and thirteen healthy controls
were included in the study. We only included
data on performance of the index test to
discriminate between patients with MCI who
convert to dementia and those who remained
stable.
No inclusion or exclusion criteria described
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
29 participants diagnosed by Petersen 2004 criteria: all
patients had subjective memory impairment that was
confirmed in neuropsychological testing, and some
patients had mild decline in other cognitive domains.
Clinical Dementia Rating (CDR) was 0.5, global cognition
was normal, activities of daily living were not impaired, and
no subject had dementia at baseline
Gender: 11 women, 18 men
Age: total sample 71.3±6.4 years; MCI converters
73.6±7.2 years; non-MCI converters 70.8±4.9 years
APOE ε4 carrier: total sample 17; MCI converters 14; non-
MCI converters 3
MMSE: total sample 26.9±1.6; MCI converters 26.2±1.5;
non-MCI converters 27.9±1.3
Sources of referral: not reported
Setting: secondary care - outpatients (memory clinic)
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
An Advance PET scanner was used in the 3D scanning mode.ROIs were drawn on the anterior and
posterior cingulate, lateral frontal cortex, caudate nucleus, putamen, thalamus, lateral temporal cortex,
parietal cortex, medial temporal lobe, and pons. Average regional ratio values of 11C-PIB uptake were
calculated using these ROIs from spatially normalised parametric ratio images
Time between PIB injection and PET acquisition: 90 minutes.
PIB administration dose: not reported
Threshold: region-to-cerebellum ratio≥1.5 (PIB retention detecting regions: global cortex, caudate
nucleus, putamen, thalamus, pons). Threshold determined at baseline
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease
dementia (conversion from MCI to AD)
Reference standard: NINCDS-ADRDA
criteria; DSM-IV criteria
Unclear whether clinicians conducting
follow-up were aware of PIB-PET analysis
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
It was not clear whether all participants received the
both reference standards
Duration of follow-up: 2 years
Number included in analysis: 29 MCI: 17 MCI
converted to AD and 12 remained stable
1) Anterior cingulate: sensitivity=82%;
specificity=58%
TP=14; FP=5; FN=3; TN=7
2) Posterior cingulate: sensitivity=94%;
specificity=58%
TP=16; FP=5; FN=1; TN=7
3) Lateral frontal cortex: sensitivity=65%;
specificity=67%
TP=11; FP=4; FN=6; TN=8
4) Parietal cortex: sensitivity=41%; specificity=67%
TP=7; FP=4; FN=11; TN=8
5) Temporal cortex: 53%; specificity=67%
TP=9; FP=4; FN=8; TN=8
Loss to follow-up: data appear to have been included
for all 29 participants
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Okello 2009
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A. Risk of Bias
Patient Sampling
Thirty-one participants were recruited from
UK and Finnish Hospitals. No further details
of recruitment were reported
Patients with significant white matter disease
in the view of an experienced radiologist
were excluded from the study. No further
exclusion criteria were reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
31 MCI participants diagnosed by the Petersen 2001
criteria: subjective memory complaint by the patient,
preferably corroborated by an informant; objective memory
impairment as assessed by performance below age-
matched normals on at least one neuropsychological
measure of memory; relatively normal performance in
other cognitive domains; intact activities of daily living; no
dementia. A strict cut-off score was not applied for the
definition of objective memory impairment
Gender: 19 male, 12 female
Age: total sample 69.4±7.9 years; MCI converters
71.6±6.3 years; non-MCI converters 67.9±9.0 years
APOE ε4 carrier: not reported
MMSE: total sample 27.5±1.5; MCI converters 27.1±1.5;
non-MCI converters 27.9±1.3
Sources of referral: not reported
Setting: secondary - inpatients (three UK hospitals and one
Finland hospital)
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
All UK participants were scanned using a Siemens ECAT EXACT HR+ camera in 3-dimensional
acquisition mode. The Finland sample were scanned with a GE advance camera, using previously
described protocol (Kemppainen 2006)
Time between PIB injection and PET acquisition: 90 minutes for DVR; 40-60 minutes for SUVR
PIB administration dose: 367±25 MBq in UK; 487±44 MBq in Finland
Threshold: region to cerebellum ratio ≥ 2SD greater than the control mean in all 6 ROIs (regions of
interest). PIB retention ratio values for each MCI participant were compared to that of the control mean
of their scanning site (visual assessment)
Threshold determined at baseline
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's dementia
(conversion from MCI to Alzheimer's
dementia)
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of PIB-PET analysis
results
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
All participants received the same reference
standard
Duration of follow-up: total sample: mean
2.68±0.6 years (32.2±7.2 months), range 1-3
years; mean 2.9±0.5 years in converters; 2.5±0.7
years in non-converters
At follow-up: 15 MCI-converters and 17 MCI-
nonconverters
Number included in analysis=31: 17 with positive
PIB tests: 14 MCI-AD, 3 MCI-MCI; 14 with
negative PIB tests: 1 MCI-AD, 13 MCI-MCI
TP=14; FP=3; FN=1; TN=13
Loss to follow-up: data appeared to have been
reported for all 31 participants
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Ossenkoppele 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
At baseline 15 participants were included in each
group: MCI, AD and controls. No further details of
patient sampling and recruitment were reported.
We only included data on performance of the index
test to discriminate between patients with MCI who
convert to dementia and those who remained stable
Exclusion criteria were a history of major psychiatric
or neurological illness (other than AD) and the use of
nonsteroidal antiinflammatory drugs Patients with
severe vascular events during the follow-up period,
such as stroke or haemorrhage, were also excluded
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
15 participants diagnosed by the Petersen
1999 criteria
Gender: male 9; female 3
Age: 67±7
APOE ε4 carrier: 8
MMSE: 27±3
Education: median (range): 6 (3-7)
Sources of referral: not reported
Setting: not reported
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
A dynamic emission scan in three-dimensional acquisition mode was used
Time between PIB injection and PET acquisition: 90 minutes
PIB administration dose: 351± 82 MBq
Threshold: Visual assessment. 11CPIB scans were classified as either positive or negative, based on
visual inspection of parametric BPND images by a trained nuclear medicine physician. Not reported
when threshold was determined
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclear
risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
AD or other type of dementia
Reference standards: NINCDS-ADRDA
criteria for AD (McKhann 1984);
Reference standard for the clinical criteria
for FTD not reported
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 2.5 years (range
2.0–4.0 years)
Number included in analysis: 12 MCI: 5
PIB+: 4 MCI-AD, 1MCI-non-converter: 7
PIB-: 1 MCI-FTD; 6 MCI-non-converters
Conversion from MCI to AD: 5 PIB+: 4 MCI-
converters and 1 MCI-non-converter; 7 PIB-
: 0 MCI-converters and 7 MCI-non-
converters (6 MCI-MCI; 1 MCI-FTD)
TP=4; FP=1; FN=0; TN=7
Conversion from MCI to all dementia: 5
PIB+: 4 MCI-converters and 1 MCI non-
converter; 7 PIB-: 1 MCI-converter and 6
MCI- non-converters. Two out of seven
MCI-non-converters converted to
‘cognitively improved’ and five remained
stable
TP=4; FP=1; FN=1; TN=6
Loss to follow-up: 3 MCI patients refused to
participate in the follow-up study due to lack
of motivation
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators contacted; they provided requested data tor the 2X2 table to be
completed and confirmed there are no overlapping patients with the Ossencoppele
2012a study; email from Dr Ossenkopele on 5/3/13
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A. Risk of Bias
Patient Sampling
154 participants included from the outpatient
memory clinic of the VU University Medical
centre for assessing the impact of molecular
imaging on the diagnostic process. Among
those participants there were 30 MCI
participants. No further details of patient
sampling and recruitment were reported.
We only included data on performance of the
index test to discriminate between patients
with MCI who convert to dementia and those
who remained stable.
Exclusion criteria: major clinical and
psychiatric disorders, recent vascular events
and excessive substance abuse
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
30 MCI participants diagnosed by the
Petersen 2001 criteria
Gender: male 23; female 7
Age: 64±9
APOE ε4 carrier: not reported
MMSE: 27±2
Sources of referral: not reported
Setting: secondary care - outpatients
(memory clinic)
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
A dynamic emission scan in three-dimensional acquisition mode was used
Time between PIB injection and PET acquisition: 90 minutes
PIB administration dose: 367± 43 MBq at baseline
Threshold: Visual assessment: [11C]PIB PET scans were rated as either PIB-positive (PIB1; binding in
more than one cortical brain region; i.e., frontal, parietal, temporal, or occipital) or PIB-negative (PIB2,
predominantly white matter binding), based on visual inspection of parametric BPND images by a
trained nuclear medicine physician. Not reported when threshold was determined.
Index test was conducted at baseline and at follow up. It was not reported whether the index test
baseline results were interpreted without knowledge of the results of the reference standard.
Outcome measures were changes in clinical diagnosis and confidence in that diagnosis before and
after disclosing PET results. The main focus of this study was not ‘conversion from MCI to dementia;
however, the author provided us with the relevant information for creating 2X2 table and, therefore,
this study has been included.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
AD or other type of dementia
Reference standards: not explicitly stated,
although NINCDS-ADRDA criteria for AD
(McKhann 1984), Neary 1998 criteria for
FTD were baseline diagnostic criteria
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 2 years
Number included in analysis: 12 MCI: 7
PIB+: 6 MCI-AD and 1 MCI-MCI; 5 PIB-: 1
MCI-FTD and 2 MCI-MCI and 1 MCI-
cognitively improved and 1MCI-psychiatric
disorder
Conversion from MCI to AD: 7 PIB+: 6
MCI-converters and 1 MCI-non-converter;
5 PIB-: 0 MCI-converters and 5 MCI-non-
converters
TP=6; FP=1; FN=0; TN=5
Conversion from MCI to all dementia: 7
PIB+: 6 MCI-converters and 1 MCI non-
converter; 5 PIB-: 1 MCI-converter and 4
MCI- non-converters.
TP=6; FP=1; FN=1; TN=4
Loss to follow-up: 18 MCI patients. No
further information
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Unclear
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes The trial investigators contacted; they provided requested data tor the 2X2 table to be
completed and confirmed there are no overlapping patients with the Ossencoppele
2012 study; email from Dr Ossenkopele on 5/3/13
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A. Risk of Bias
Patient Sampling
MCI and DAT participants were recruited from
the Austin Health Memory Disorders Clinic.
Controls were recruited by advertisement and
from the Melbourne Healthy Aging Study. We
only included data on performance of the index
test to discriminate between patients with MCI
who convert to dementia and those who
remained stable..
No further details on recruitment are presented.
No inclusion or exclusion criteria are described
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
67 MCI participants diagnosed by the Petersen
1999 criteria. Demographic data were reported for
65 MCI participants who were further classified as a
amnestic MCI (n=53) or nonamnestic MCI (4
nonamnestic single domain and 8 nonamnestic
multiple domain)
Gender: 36 male, 29 female
Age:73.4±8.5 years
APOE ε4 carrier: 41 (63%)
MMSE: 26.5±2.9
Years of education: 12.2±4.3
Sources of referral: mixed: advertisements and the
Melbourne Healthy Aging Study
Setting: secondary care - outpatients (memory
clinic)
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
Standardized uptake values (SUVs) for PiB were calculated for all brain regions examined and SUV
ratios (SUVRs) were generated by dividing all regional SUVs by the cerebellar cortex SUV. ROI
measurements were averaged across both hemispheres. Neocortical Ab burden was expressed as the
average SUVR of the area-weighted mean of frontal, and posterior cingulate regions
Time between PIB injection and PET acquisition: 40 minutes
PIB administration dose: 370MBq
Threshold: neocortical standardised uptake values ratio (SUVR) > 1.5 (PIB retention detecting regions:
global cortex). To define a PiB SUVR cut-off, a hierarchical cluster analysis was performed on all
healthy controls. Threshold determined at baseline and was consistent with cutoff values used in
previous PIB-PET studies (Bourgeat 2010; Jack 2008)
Index test was conducted at baseline
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: Alzheimer's disease dementia and
other forms of dementia
Reference standard: NINCDS-ADRDA criteria for
Alzheimer's disease dementia. Neurologist and a
neuropsychologist conducting follow-up blind to PIB
status
Reference standards for VD and FTD not reported
Is the reference standards likely to correctly classify the target
condition? Unclear
Were the reference standard results interpreted without
knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean was 20±3
months.
All participants received the same reference
standard
Number included in analysis: 65 MCI: 45
'amyloid positive': 30 MCI-AD, 15 MCI-MCI;
20 'amyloid negative': 5 converters (1 MCI-
AD; 1 MCI-VD; 1 MCI-FTD; 2 LBD); 15 non-
converters (13 MCI-MCI; 2 MCI-HC)
Conversion from MCI to AD: 45 PIB+: 30
MCI-converters (MCI-AD) and 15 MCI-non-
converter (MCI-MCI); 20 PIB-: 1 MCI-
converter (MCI-AD) and 19 MCI-non-
converters (1 MCI-VD; 1 MCI-FTD; 2 LBD;
13 MCI-MCI; 2 MCI-HC)
TP=30; FP=15; FN=1; TN=19
Conversion from MCI to all dementia: 45
PIB+: 30 MCI-converters and 15 MCI non-
converter; 20 PIB-: 5 MCI-converters (1 MCI-
AD; 1 MCI-VD; 1 MCI-FTD; 2 LBD) and 15
MCI- non-converters. Two out of seven MCI-
non-converters converted to ‘cognitively
improved’ and five remained stable
TP=30; FP=15; FN=5; TN=15
Loss to follow-up: 2 MCI participants: 1
participant was withdrawn by their caregivers
and 1 participant was not contactable
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Wolk 2009
Patient Selection
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A. Risk of Bias
Patient Sampling
Twenty-six patients with MCI, 22 patients with mild
Alzheimer's disease and 35 healthy elderly participants.
The clinical diagnosis for those who entered the University
of Pittsburgh Alzheimer’s Disease Research Center
(ADRC) was made through consensus at a conference.
The conference was attended by neurologists,
psychiatrists, and neuropsychologists experienced in the
diagnosis of dementia. Assessment included medical and
neurological history and examination, a semi-structured
psychiatric evaluation, and psychometric testing.
We only included data on performance of the index test to
discriminate between patients with MCI who convert to
dementia and those who remained stable. MCI participants
were recruited from ADRC. Nine participants already had
PiB PET data. No further details of recruitment were
reported.
Inclusion criteria: age 40 years or older, proficient English
speaker, and a reliable caregiver
Exclusion criteria: lifetime history of schizophrenia, manic-
depressive disorder, or schizoaffective disorder; prior
electroconvulsive therapy; current substance
abuse/dependence or within 2 years of symptom onset;
and any medical condition that could affect
neuropsychological testing
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
26 MCI participants diagnosed by the Petersen
2004 and modified Petersen (Winblad 2004)
criteria. MCI-multiple cognitive domain cases
were reviewed and subdivided according to the
Gauthier et al. scheme (Gauthier 2008). No
strict cutoffs on psycho-metric testing were
used. Impairment was "generally" less than 1.5
SDs of University of Pittsburgh ADRC age-
adjusted norms (13 single-domain amnestic-
MCI; 6 multi-domain a-MCI; 7 non-amnestic
MCI). The clinicians were aware of the previous
year’s diagnosis at follow-up consensus
discussions
Gender: total 7 female and 19 male; 3 of 19
amnestic-MCI is female, 4 of 7 nonamnestic-
MCI is female
Age: total 70.2±8.8 years; amnestic-MCI is
71.6±8.0,  noamnestic-MCI is 69.6±9.2
APOE ε4 carrier: total 14 APOE4 carrier; 9 out
of 11 a-MCI Amyloid-Positive; 4 out of 8 a-MCI
Amyloid-Negative; 0 out of 3 na-MCIAmyloid-
Positive; 1 out of 3 na-MCIAmyloid-Negative.
One a-MCI patient did not have ApoE results
available
MMSE: total  27.3±1.9 (calculated by ZS);
amnestic-MCI is 27.2±2.1; noamnestic-MCI is
27.7±1.1
Education: mean 16.6± 3.3 years for a-MCI;
mean 18.7± 2.6 years for na-MCI
Sources of referral: not reported
Setting: tertiary setting - Pittsburg Alzheimer’s
Disease Research Center
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
PET imaging was conducted on a Siemens/CTI ECAT HR+(Siemens, Erlangen, Germany). The
scanner was equipped with Neuro-insert (CTI PET Systems, Knoxville, TN) to reduce the contribution
of scattered photons
Time between PIB injection and PET acquisition: 90 minutes for DVR; 40–60 minutes for SUR
PIB administration dose: 14.3±2.2mCi
Threshold:DVR or SUR of region of interest > upper-inner fence of the control subjects. To avoid a
strict cutoff, authors defined an intermediate range 2.5% greater than and less than this cutoff
(Aizenstein 2008). Subjects who had a PiB DVR value exceeding the intermediate range in any ROI
was defined as amyloid-positive, and those under the intermediate range were defined as amyloid-
negative. For the two MCI patients who did not have DVR values SUV ratios were used to determine
cutoffs (these are not described). Threshold determined at baseline.
ROIs were defined on a co-registered magnetic resonance image, as described previously (Price
2005); these included frontal, anterior cingulate, precuneus, lateral temporal, parietal, medial temporal,
occipital, and sensorimotor cortices, anterior ventral striatum, subcortical white matter, and pons. A
cerebellar ROI served as reference region, and the pons and subcortical white matter ROIs were
measures of nonspecific ligand retention. Scanning was performed within approximately 6 months of
ADRC evaluation (mean SD, 14.9 ± 7.3 weeks)
Index test was conducted at baseline and the results were available for all participants
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low
concern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to Alzheimer’s
disease dementia
Reference standard: the clinical diagnosis was made
through consensus at a conference, attended by
neurologists, psychiatrists and neuropsychologists
experienced in the diagnosis of dementia
It was not reported whether the reference standard results
were interpreted without knowledge of the results of the
index test
Is the reference standards likely to correctly classify the target
condition? Unclear
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Low
concern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 21.2 ± 16.0
months subsequent to their PiB scan
All participants received the same reference
standard
Number included in analysis: 23 MCI: 13
'amyloid positive': 5 MCI-AD, 8 MCI-MCI; 10
'amyloid negative': 0 MCI-AD; 10 non-
converters (7 MCI-MCI; 3 MCI-normal)
TP=5; FP=8; FN=0; TN=10
Loss to follow-up: 3 MCI participants; they did
not have follow-up assessment; two of those
patients did not complete the entire protocol
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Footnotes
Characteristics of excluded studies 
Choo 2011
Reason for exclusion Target condition: not looking at conversion from MCI to dementia. The focus of the
study is the annual change in PIB retention
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Driscoll 2011
Reason for exclusion Target condition: not looking at conversion from MCI to dementia
 
Ellis 2010
Reason for exclusion Target condition: not looking at conversion from MCI to dementia
 
Fagan 2007
Reason for exclusion Index test: PIB-PET test performed at follow-up
Target condition: not looking at conversion from MCI to dementia
 
Kadir 2012
Reason for exclusion Target condition: not looking at conversion from MCI to dementia
 
Kadir 2012a
Reason for exclusion Target condition: not looking at conversion from MCI to dementia
 
Resnick 2010
Reason for exclusion Target condition: not looking at conversion from MCI to dementia. The focus of the
study is the association abeta deposition and cognitive decline
 
Rowe 2010
Reason for exclusion Target condition: not looking at conversion from MCI to dementia
 
Shinotoh 2011
Reason for exclusion Index test: threshold not used
Target condition: not looking at conversion from MCI to dementia. The focus of the
study is the change in PIB retention over time
 
Sojkova 2008
Reason for exclusion Participants: 28 non-demented subjects; only 6 participants with mild cognitive
impairment (CDR=0.5) at baseline
Target condition: not looking at conversion to dementia. The focus of the study is the
annual change in PIB retention in high and low PIB retention groups
 
Sojkova 2011
Reason for exclusion Target condition: not looking at conversion from MCI to dementia. The focus of the
study is the annual change in PIB retention over time
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
DeKosky 2006
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Study name Human amyloid-imaging studies with Pittsburgh Compound-B in Mild Cognitive
Impairment (MCI): Is MCI the critical period of amyloid plaque deposition?
 
Target condition and reference
standard(s)
Target condition: conversion from MCI to Alzheimer's disease dementia
Reference standard: not reported
 
Index and comparator tests 11C-PIB-PET
 
Starting date not reported
 
Contact information sd3zc@hscmail.mcc.virginia.edu
 
Notes  
Footnotes
Summary of results tables
1 Performance of 11C-PIB-PET amyloid biomarker for detecting Alzheimer's disease dementia and predicting
progression to dementia in patients with MCI
What is the diagnostic accuracy of 11C-PIB-PET amyloid biomarker for detecting Alzheimer's disease and predicting
progression to dementia in patients with MCI?
Descriptive 
Patient population Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR=0.5 or any 16
definitions included by Matthews (Matthews 2008)
Sources of referral · primary care centres in community (n=1)
· mixed (community/primary care/secondary care/other) (n=3)
· not reported (n=5)
MCI criteria · Petersen criteria (n=6)
· Petersen and modified Petersen criteria (n=1)
· modified Petersen criteria (n=1)
· CDR=0.5 criteria and modified Petersen criteria (n=1)
Sampling
procedure
· consecutive or random (n=1)
· not consecutive or random (n=1)
· unclear (n=7)
Prior testing The only testing prior performing the 11C-PIB-PET biomarker was the application of diagnostic criteria
for identifying participants with MCI
Settings · secondary care – outpatients (n=5)
· secondary care – inpatients (n=1)
· mixed setting (n=1)
· tertiary setting (n=1)
· not reported (n=1)
Index tests 11C-PIB-PET
Threshold pre-
specified at
baseline
· Yes (n=6)
· No (n=1)
· Not reported (n=2)
Threshold
interpretation
· quantitative (n=5)
· visual (n=4)
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Threshold · DVR (Distribution Volume Ratio) of ROI: >1.5 (n=1)
· SUVR (Standardised Uptake Volume ratio) of ROI: > 1.5 (n=1)
· not specified analytical approach of ROI: 1.4; >1.5; >1.6 (n=3)
· RATIO > 2SD than control mean in 6 ROI (n=1)
· DVR or SVR of ROI > upper-inner fence of the control (n=1)
· not reported (n=2)
PIB retention
region
· Global cortex (n=5)
· Global cortex and other brain region (n=4)
Reference
standard
For Alzheimer’s disease dementia:
· NINCDS-ADRDA (n=7)
· DSM-IV and/ or NINCDS-ADRDA (n=1)
· unclear (n=1)
For FTD: Land criteria or Neary 1998 criteria
Target condition Conversion from MCI to Alzheimer’s disease dementia and any other forms of dementia
Included studies Prospectively well-defined cohorts with any accepted definition of MCI (as above). Nine studies (N=300
participants) were included. Number included in analysis: 274
Quality concerns Patient characteristics and conduct of the index and reference standard were poorly reported.
Applicability concerns were generally low.
Limitations Limited investigation of heterogeneity due to insufficient number of studies. Lack of common thresholds.
Test Studies Cases/
Participants
Median / lower quartile /
upper quartile specificity
from included studies
Sensitivity 
(95% CI)1 at / lower
quartile / upper quartile
median specificity 
Consequences in a cohort of 100
Median
proportion
converting
(range)2
Missed
cases3
Over
diagnosed3
Alzheimer's disease
11C-PIB-
PET
9 112/274 58 (median) 96 (87, 99) 34 (33 to 48) 1 28
11C-PIB-
PET 9 112/274 56 (lower quartile) 96 (88, 99)    
11C-PIB-
PET 9 112/274 81 (upper quartile) 89 (68, 97)    
Investigation of heterogeneity: The planned investigations were not possible due to the limited number of studies available
for each analysis. For type of reference standard, most studies belonged to the same subgroup and so we conducted
sensitivity.
Conclusions: 11C PIB-PET scan is not an accurate test for detecting conversion from MCI to Alzheimer's disease or other
forms of dementia. The strength of the evidence is weak because of considerable variation in study methods and unclear
methodological quality due to poor reporting. There is a need for conducting studies using standardised PIB-PET
methodology in larger populations.
Footnotes
1
 Meta-analytic estimate of sensitivity derived from the HSROC model at a fixed value of specificity. Summary estimates of
sensitivity and specificity were not computed because the studies that contributed to the estimation of the summary ROC
curve used various thresholds.
2 The median proportion converting (reported in percentage) and range were computed using all the studies included in the
analysis for each target condition.
3
 Missed and over-diagnosed numbers were computed using the median proportion converting to each target condition.
Additional tables 
1 Demographic and patient characteristics
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Study N/n Age 
Gender
M (%)
MMSE
score
APOE
Ɛ4
carrier
(%)
Years of
education/
Verhage's
classification*
MCI
diagnostic
criteria
Sampling Sources ofreferral Setting
Forsberg 2010
(Sweden)
 
21/21
63.3 ±
7.8 8 (38.1) 28.2±1.4
14
(66.7) 12.7 ±3.1
Winblad
2004
Not
reported
Primary care
centers in
community
Secondary
care:
outpatients
Grimmer 2013
(Germany) 28/2867.9±7.4 14 (50) 26.0±3.2
Not
reported
11.8 ±2.2
(range 8-17)
CDR=0.5
and
Winbald
2004
Not
reported
GP surgeries or
specialists or
other institutions
Secondary
care:
outpatients
Jack 2010
(USA) 53/5375
Not
reported 27
Not
reported 16
Petersen
2010
ADNI
participants Mixed
Mixed: 13
different
sites
Koivunen 2011
(Finland) 29/29
71.3 ±
6.4
18
(62.1) 26.9±1.6
17
(58.6) Not reported
Petersen
2004
Consecutive
sample Not reported
Secondary
care:
outpatients:
memory
clinic:
Okello 2009
(UK/Finland) 31/31
69.4 ±
7.9
19
(61.3) 27.5±1.5
Not
reported Not reported
Petersen
2010
Not
reported Not reported
Secondary
care:
inpatients
*Ossenkoppele
2012
(Netherland)
15/1267±7 Not
reported 27±3
Not
reported
median 6
(range 3-7)*
Petersen
2001
Not
reported Not reported
Not
reported
Ossenkoppele
2012a
(Netherland)
30/1264±9 Not
reported 27±2
Not
reported Not reported
Petersen
1999
Not
reported Not reported
Secondary
care:
outpatients:
memory
clinic:
Villemagne
2011
(Australia)
67/6573.4±8.5 36(55.4) 26.5±2.9 41 (63) 12.2 ±4.3
Petersen
1999
Not
reported
Mixed
(advertisements
and the
Melbourne
Healthy Aging
Study
Secondary
care:
outpatients:
memory
clinic:
Wolk 2009
(USA) 26/2370.2±8.8
Not
reported 27.3±1.9
Not
reported 17.2 ±3.2
Petersen
2004;
Winbald
2004
Not
reported Not reported
Tertiary
setting:
Pittsburg
ADRC
Footnotes
N=number of MCI participants at baseline; n=number of participants included in analysis at follow-up; M=number of males
*Study used Verhage's classification on a scale of 1-7 (means 6; range 3-7), not years, for the unit of education
2 Index test and number of converters to Alzheimer's disease dementia
Study Threshold 
(pre-specified
Yes/No)
Measure of
PIB amyloid
retention
Image
analysis
Time
between
PIB
injection
and PET
acquisition
(min)
PIB dosePIB retention
detecting
regions
Number
of PIB
positive
(%)
Number of
converters
(%)
Duration
of follow-
up
Mean
(months) /
Maximum
(years)
Forsberg 2010
(Sweden)
Not specified
analytical
approach of
ROI to-
cerebellar ratio
>1.6 (No)
ROI to-
cerebellar
ratio
SPM2 and
MATLAB
7.1
60 300 MBq Global cortex
and thalamus
11
(52.4)
7 (33.3) 33.3 ±19.3
/ Not
reported
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Grimmer 2013
(Germany)
Not specified
analytical
approach of
ROI to-
cerebellar
vermis ratio of
1.4 (Yes)
ROI to-
cerebellar
ratio
Not
reported
40-60 628 MBq
(range
385 to
723
MBq)
Global cortex 17
(60.7)
9 (32.2) 31.2 ±7.8 /
Not
reported
Jack 2010
(USA)
DVR of ROI to-
cerebellar ratio
>1.5 (Yes)
Average
neocortical
to-cerebellar
ratio
Automated
image
processing
pipeline
Range
50-70
Not
reported
Global cortex 34
(64.2)
18 (34.0) Not
reported /
1.7
(median)
Koivunen
2011 (Finland)
Not specified
analytical
approach of
ROI to-
cerebellar ratio
> 1.5 (Yes)
Posterior
cingulate
to-cerebellar
ratio
SPM2 90 Not
reported
Global
cortex,
caudate
nucleus,
putamen,
thalamus,
pons
21
(72.4)
17 (58.6) Not
reported /
2
Okello 2009
(UK/Finland)
RATIO > 2 SD
greater
than the
control mean in
all 6 ROI (visual
interpretation)
(Yes)
RATIO SPM Range
60–90
367 ± 25
MBq
Global cortex 17
(54.8)
15 (48.4) 27.5±1.5 /
3 (range
1-3)
Ossenkoppele
2012
(Netherland)
 
Not reported
(visual
interpretation)
Visual
inspection
of
parametric
BPND images
by a trained
nuclear
medicine
physician
BPND 90 351 ± 82
MBq
Global
cortex,
frontal,
parietal and
lateral
temporal and
medial
temporal lobe
and posterior
cingulate
5 (41) 4 (33.3) 30.0±6.0 /
4 (range
2-4)
Ossenkoppele
2012a
(Netherland)
 
Not reported
(visual
interpretation)
Visual
inspection
of
parametric
BPND and
SUVr images
by a trained
nuclear
medicine
physician
BPND Range
60-90
367 ± 43
MBq
Frontal,
parietal,
temporal and
occipital lobe
7 (58.3) 6 (50.0) Not
reported /
2
Villemagne
2011
(Australia)
SUV of ROI
>1.5 (Yes)
Average
neocortical
to-cerebellar
ratio
MilxView 40 370 MBq Global cortex 45
(69.2)
31 (68.9) 20.0±3.0 /
Not
reported
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Wolk 2009
(USA)
DVR or SUV of
ROI
> upper-inner
fence of the
controls; an
intermediate
range 2.5%
greater than
and less than
this cut-off
subjects
(visual
interpretation)
(Yes)
ROI to-
cerebellar
ratio
SPM5 90 for DVR;
range
40–60 for
SUVR
14.3 ±
2.2 mCi
Global
cortex,
anterior
ventral
striatum,
subcortical
white matter,
pons
13
(56.5)
5 (21.7) 21.2±16.0
/
Not
reported
Footnotes
3 Index test: Criteria for quantitative or visual interpretation and PIB retention in brain ROI areas
Threshold for a positive PIB-PET test
Quantitative interpretation:
1. DVR (Distribution Volume Ratio) of ROI: >1.5 (n=1)
2. SUVR (Standardised Uptake Volume ratio) of ROI: > 1.5 (n=1)
3. Not specified analytical approach of ROI: 1.4; >1.5; >1.6 (n=3)
 
Visual interpretation:
1. RATIO > 2SD than control mean in 6 ROI (n=1)
2. DVR or SVR of ROI > upper-inner fence of the control (n=1)
3. Threshold not reported in 2 studies
 
 
Measure of PIB amyloid retention
 
PIB retention in brain areas (ROI)
1. ROI to cerebellar ratio (n=3) Global cortex
Global cortex and thalamus
Global cortex, anterior ventral striatum, subcortical white matter, pons
2. Average neocortical to cerebellar ratio (n=2) Global cortex
3. Posterior cingulate to cerebellar ratio (n=1) Global cortex, caudate nucleus, putamen, thalamus, pons
4. RATIO (n=1) Global cortex
5. Visual inspection of parametric BPND images
(n=1)
Global cortex, frontal, parietal and lateral temporal and medial temporal
lobe and posterior cingulate
6. Visual inspection of parametric BPND and
SUVR images (n=1)
Frontal, parietal, temporal and occipital
Footnotes
4 Sensitivity and likelihood ratios for 11C-PIB-PET at fixed values of specificity for Alzhemer's dementia
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Statistic Fixed value of
specificity %
Estimated sensitivity % (95%
confidence interval)
Positive likelihood ratio (95%
confidence interval)
Negative likelihood ratio (95%
confidence interval)
All studies (n = 9; cases = 112 ; non-cases = 162)
Lower
quartile
56 96 (88, 99) 2.19 (2.09, 2.29) 0.07 (0.02, 0.23)
Median 58 96 (87, 99) 2.29 (2.17, 2.41) 0.07 (0.02, 0.24)
Upper
quartile
81 89 (68, 97) 4.66 (4.03, 5.39) 0.14 (0.05, 0.44)
Sensitivity analyses   
Reference standard NINCDS-ADRDA only (n = 7; cases = 89; non-cases = 144) 
Lower
quartile
56 96 (84, 99) 2.18 (2.06, 2.32) 0.07 (0.02, 0.30)
Median 58 96 (83, 99) 2.28 (2.14, 2.43) 0.07 (0.02, 0.31)
Upper
quartile
81 88 (62, 97) 4.62 (3.86, 5.55) 0.15 (0.04, 0.56)
Threshold pre-specified (n = 7; cases = 101; non-cases = 140) 
Lower
quartile 56 95 (84, 99) 2.16 (2.02, 2.30) 0.09 (0.03, 0.30)
Median 58 94 (83, 98) 2.25 (2.10, 2.41) 0.10 (0.03, 0.32)
Upper
quartile
81 85 (61, 95) 4.46 (3.67, 5.42) 0.19 (0.06, 0.55)
Footnotes
The middle 50% of specificities from the studies are between the lower and upper quartile, i.e. the interquartile range
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Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
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across included studies.
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Summary ROC plot of 11C-PIB-PET AD dementia.
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Summary ROC Plot of 11C-PIB-PET All dementia. Each point represents a pair of sensitivity and specificity for each study,
and the cross hairs correspond to their 95% CIs.
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Source
 
Search strategy Hits
retrieved
1. MEDLINE In-process and
other non-indexed citations
and MEDLINE 1950-present
(OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab.
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (animals not (humans and animals)).sh.
34. 32 not 33
35. (2012* or 2013*).ed.
36. 34 and 35
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Source
 
Search strategy Hits
retrieved
2. EMBASE
1980-2012 April 10 (OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2012* or 2013*).em.
34. 32 and 33
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Source
 
Search strategy Hits
retrieved
3. PsycINFO
1806-April week 2 2012
(OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2012* or 2013*).up.
34. 32 and 33
 
276
4. Biosis previews (ISI Web
of Knowledge)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR "PiB-PET"
OR "PET-PiB" OR "amyloid ligand*" OR "[11C]PiB" OR "amyloid deposition") AND
Topic=(alzheimer* OR AD OR dement* OR lewy OR VAD OR VCI OR cognit* OR
MCI OR memory) AND Year Published=(2012-2013)
Timespan=All Years. Databases=BIOSIS Previews.
Lemmatization=On  
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Source
 
Search strategy Hits
retrieved
5. Web of Science and
conference proceedings
(1945-present)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR "PiB-PET"
OR "PET-PiB" OR "amyloid ligand*" OR "[11C]PiB" OR "amyloid deposition") AND
Topic=(alzheimer* OR AD OR dement* OR lewy OR VAD OR VCI OR cognit* OR
MCI OR memory) AND Year Published=(2012-2013)
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH.
Lemmatization=On  
 
 
276
6. LILACS (BIREME) PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR PiB-PET OR PET-
PiB OR "amyloid ligand*" OR "amyloid deposition" [Words]
 
7
TOTAL before de-duplication 2737
TOTAL after de-duplication and first-assessment 74
April 2012
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Source
 
Search strategy Hits
retrieved
1. MEDLINE In-process and
other non-indexed citations
and MEDLINE 1950-present
(OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab.
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (animals not (humans and animals)).sh.
34. 32 not 33
35. (2011* or 2012*).ed.
36. 34 and 35
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Source
 
Search strategy Hits
retrieved
2. EMBASE
1980-2012 April 10 (OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2011* or 2012*).em.
34. 32 and 33
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Source
 
Search strategy Hits
retrieved
3. PsycINFO
1806-April week 2 2012
(OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5" or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2011* or 2012*).up.
34. 32 and 33
 
298
4. Biosis previews (ISI Web
of Knowledge)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR "PiB-
PET" OR "PET-PiB" OR "amyloid ligand*" OR "[11C]PiB" OR "amyloid
deposition") AND Topic=(alzheimer* OR AD OR dement* OR lewy OR VAD OR
VCI OR cognit* OR MCI OR memory) AND Year Published=(2011-2012)
Timespan=All Years. Databases=BIOSIS Previews.
Lemmatization=On  
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Source
 
Search strategy Hits
retrieved
5. Web of Science and
conference proceedings
(1945-present)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR "PiB-
PET" OR "PET-PiB" OR "amyloid ligand*" OR "[11C]PiB" OR "amyloid
deposition") AND Topic=(alzheimer* OR AD OR dement* OR lewy OR VAD OR
VCI OR cognit* OR MCI OR memory) AND Year Published=(2011-2012)
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH.
Lemmatization=On  
 
321
6. LILACS (BIREME) PiB OR PIB OR "Pittsburgh compound B" OR "C Pittsburgh" OR PiB-PET OR
PET-PiB OR "amyloid ligand*" OR "amyloid deposition" [Words]
 
193-187=6
TOTAL before de-duplication 2517
TOTAL after de-duplication and first-assessment 28
September 2011
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Source
 
Search strategy Hits retrieved
1. MEDLINE In-process and other non-indexed
citations and MEDLINE 1950-present (OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab.
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission
tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or
LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3
(declin* or impair* or los* or deteriorat* or degenerat*
or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5"
or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. (2003* or 2004* or 2005* or 2006* or 2007* or
2008* or 2009* or 2010* or 2011*).ed.
33. 10 and 31 and 32
34. (animals not (humans and animals)).sh.
35. 33 not 34
2510
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Source
 
Search strategy Hits retrieved
2. EMBASE
1980-2011 week 34 (OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission
tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or
LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3
(declin* or impair* or los* or deteriorat* or degenerat*
or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5"
or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2003* or 2004* or 2005* or 2006* or 2007* or
2008* or 2009* or 2010* or 2011*).em.
34. 32 and 33
35. limit 34 to human
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Source
 
Search strategy Hits retrieved
3. PsycINFO
1806-February week 2 2011 (OvidSP)
1. Positron-Emission Tomography/
2. (PiB or PIB).ti,ab. or pittsburgh compound B/
3. "Pittsburgh compound B".ti,ab.
4. "C Pittsburgh".ti,ab.
5. (PIB-PET or PET-PIB).ti,ab.
6. "amyloid deposition".ti,ab.
7. "[11C]PIB".ti,ab.
8. "amyloid ligand*".ti,ab.
9. ((PET and (scan* or imag*)) or "positron emission
tomography").ti,ab.
10. or/1-9
11. (alzheimer* or dement* or AD or lewy* or DLB or
LBD).ti,ab.
12. exp dementia/
13. ((cognit* or memory or cerebr* or mental*) adj3
(declin* or impair* or los* or deteriorat* or degenerat*
or complain* or disturb* or disorder*)).ti,ab.
14. MCI.ti,ab.
15. ACMI.ti,ab.
16. ARCD.ti,ab.
17. SMC.ti,ab.
18. CIND.ti,ab.
19. BSF.ti,ab.
20. AAMI.ti,ab.
21. LCD.ti,ab.
22. QD.ti,ab.
23. AACD.ti,ab.
24. MNCD.ti,ab.
25. MCD.ti,ab.
26. (nMCI or aMCI or mMCI).ti,ab.
27. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
28. ("CDR 0.5" or "clinical dementia rating scale 0.5"
or "0.5 CDR").ti,ab.
29. ("GDS 3" or "3 GDS").ti,ab.
30. ("global deterioration scale" and "stage 3").ti,ab.
31. or/11-30
32. 10 and 31
33. (2003* or 2004* or 2005* or 2006* or 2007* or
2008* or 2009* or 2010* or 2011*).up.
34. 32 and 33
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Source
 
Search strategy Hits retrieved
4. ISI Web of Knowledge: BIOSIS Previews (1926-
present)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR
"C Pittsburgh" OR "PiB-PET" OR "PET-PiB" OR
"amyloid ligand*" OR "[11C]PiB" OR "amyloid
deposition") AND Topic=(alzheimer* OR AD OR
dement* OR lewy OR VAD OR VCI OR cognit* OR
MCI OR memory) AND Year Published=(2003-2011)
Timespan=2003-2011. Databases=BIOSIS Previews.
Lemmatization=On  
 
826
5. ISI Web of Knowledge: Citation Databases :
Science Citation Index Expanded (SCI-EXPANDED);
Social Sciences Citation Index (SSCI); Arts &
Humanities Citation Index (A&HCI); Conference
Proceedings Citation Index- Science (CPCI-S);
Conference Proceedings Citation Index- Social
Science & Humanities (CPCI-SSH)
Topic=(PiB OR PIB OR "Pittsburgh compound B" OR
"C Pittsburgh" OR "PiB-PET" OR "PET-PiB" OR
"amyloid ligand*" OR "[11C]PiB" OR "amyloid
deposition") AND Topic=(alzheimer* OR AD OR
dement* OR lewy OR VAD OR VCI OR cognit* OR
MCI OR memory) AND Year Published=(2003-2011)
Timespan=2003-2011. Databases=BIOSIS Previews.
Lemmatization=On  
1227
6. LILACs (BIREME) PiB OR PIB OR "Pittsburgh compound B" OR "C
Pittsburgh" OR PiB-PET OR PET-PiB OR "amyloid
ligand*" OR "amyloid deposition" [Words]
187
7. Clinicaltrials.gov (www.clinicaltrials.gov) #1 11-C Pib = 3
#2 amyloid ligand OR amyloid ligands = 5
#3 radioligand = 38
#4 Pittsburgh compound = 27
 
3+5+38+27=73
TOTAL before de-duplication 9697
TOTAL after de-duplication and first-assessment 60
2 Two times two tables
Table 1: Conversion from MCI to Alzheimer’s disease dementia
Index test informationReferences standard information
ADD present ADD absent
Index test positive PIB+ who convert to ADD (TP)PIB+ who remain MCI (FP) & PIB+ who convert to non-ADD (FP)
Index test negative PIB- who convert to ADD (FN) PIB- who remain MCI (TN) & PIB- who convert to non-ADD (TN)
Table 2: Conversion from MCI to non-Alzheimer’s disease dementia
Index test informationReferences standard information
Non-ADD present Non-ADD absent
Index test positive PIB+ who convert to non-ADD (TP)PIB+ who remain MCI (FP) & PIB+ who convert to ADD (FP)
Index test negative PIB- who convert to non-ADD (FN) PIB- who remain MCI (TN) & PIB- who convert to ADD (TN)
Table 3: Conversion from MCI to any forms of dementia
Index test informationReferences standard information
Any forms of dementia present Dementia absent
Index test positive PIB+ who convert to any form of dementia (TP)PIB+ who remain MCI (FP)
Index test negative PIB- who convert to any form of dementia (FN) PIB- who remain MCI (TN)
3 Assessment of methodological quality table QUADAS-2 tool
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DOMAIN PATIENT SELECTION   INDEX TEST  REFERENCE
STANDARD
FLOW AND TIMING 
Description Describe methods of
patient selection: describe
included patients (prior
testing, presentation,
intended use of index test
and setting)
Describe the index
test and how it was
conducted and
interpreted
Describe the
reference standard
and how it was
conducted and
interpreted
Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2x2 table (refer
to flow diagram): describe the time
interval and any interventions
between index test(s) and
reference standard
Signalling
questions
(yes/no/unclear)
Was a consecutive or
random sample of patients
enrolled?
Were the index test
results interpreted
without knowledge
of the results of the
reference
standard?
Is the reference
standard likely to
correctly classify the
target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control design
avoided?
If a threshold was
used, was it pre-
specified?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
Did all patients receive a reference
standard?
Did the study avoid
inappropriate exclusions?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
Risk of bias:
High/low/ unclear
Could the selection of
patients have introduced
bias?
Could the conduct
or interpretation of
the index test have
introduced
bias?      
Could the reference
standard, its conduct,
or its interpretation
have introduced
bias?
Could the patient flow have
introduced bias? 
Concerns
regarding
applicability:
High/low/ unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns
that the index test,
its conduct, or
interpretation differ
from the review
question?
Are there concerns
that the target
condition as defined
by the reference
standard does not
match the review
question?
 
4 Anchoring statements for quality assessment of PIB-PET diagnostic studies
Table 4: Review question and inclusion criteria
Category Review Question Inclusion Criteria
Patients Participants with mild cognitive impairment, no
dementia
Participants fulfilling the criteria for the clinical diagnosis of
MCI at baseline
Index Test 11C-PIB-PET biomarker 11C-PIB-PET biomarker
Target
Condition
Alzheimer’s disease dementia (conversion
from MCI to Alzheimer’s disease dementia)
Any other forms of dementia (conversion from
MCI to any other forms of dementia
Alzheimer’s disease dementia (conversion from MCI to
Alzheimer’s disease dementia)
Any other forms of dementia (conversion from MCI to any
other forms of dementia)
Reference
Standard
NINCDS-ADRDA; DSM; ICD; McKeith criteria;
Lund criteria; NINDS-ARIEN criteria
NINCDS-ADRDA; DSM; ICD; McKeith criteria; Lund criteria;
NINDS-ARIEN criteria
Outcome N/A Data to construct 2x2 table
Study Design N/A  
Longitudinal cohort studies and
Nested case-control studies if they incorporate a delayed
verification design (case-control nested in cohort studies)
Anchoring statements for quality assessment of PIB-PET diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy review of the PIB-PET
biomarker in dementia.  These statements are designed for use with the QUADAS-2 tool and are based on the
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guidance for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia (Quinn 2014)
During the two-day, multidisciplinary focus group and the piloting/validation of the guidance, it was clear that certain issues
were key to assessing quality, while other issues were important to record but less important for assessing overall quality. 
To assist, we describe a 'weighting' system.  Where an item is weighted 'high risk' then that section of the QUADAS-2 results
table is likely to be scored as high risk of bias.  For example in dementia diagnostic test accuracy studies, ensuring that
clinicians performing dementia assessment are blinded to results of the index test is fundamental.  If this blinding was not
present then the item on the reference standard should be scored 'high risk of bias', regardless of the other contributory
elements.
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty.  In these situations
review authors will contact the relevant study teams for additional information.
Table 5: Anchoring statements to assist with assessment for risk of bias
Question Response
and
weighting
Explanation
Patient Selection
 
Was the sampling method
appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where sampling is used, the designs least likely to cause bias are consecutive
sampling or random sampling. Sampling that is based on volunteers or selecting
subjects from a clinic or research resource is prone to bias.
Was a case-control or
similar design avoided?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Designs similar to case control that may introduce bias are those designs where the
study team deliberately increase or decrease the proportion of subjects with the
target condition, which may not be representative. Some case control methods may
already be excluded if they mix subjects from various settings.
Are exclusion criteria
described and
appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Study will be automatically graded unclear if exclusions are not detailed (pending
contact with study authors). Where exclusions are detailed, the study will be graded
as “low risk” if exclusions are felt to be appropriate by the review authors. Certain
exclusions common to many studies of dementia are: medical instability; terminal
disease; alcohol/substance misuse; concomitant psychiatric diagnosis; other
neurodegenerative condition. Exclusions are not felt to be appropriate if ‘difficult to
diagnose’ patients are excluded. Post hoc and inappropriate exclusions will be
labelled “high risk” of bias.
Index Test
Was PIB-PET biomarker's
assessment /
interpretation performed
without knowledge of
clinical dementia
diagnosis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are sufficient
and full details of the blinding procedure are not required. Interpretation of the results
of the index test may be influenced by knowledge of the results of reference
standard. If the index test is always interpreted prior to the reference standard then
the person interpreting the index test cannot be aware of the results of the reference
standard and so this item could be rated as ‘yes’.
For certain index tests the result is objective and knowledge of reference standard
should not influence result, for example level of protein in cerebrospinal fluid, in this
instance the quality assessment may be “low risk” even if blinding was not achieved.
Were PIB-PET
biomarker's thresholds
pre-specified?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
For scales and biomarkers there is often a reference point (in units or categories)
above which subjects are classified as “test positive”; this may be referred to as
threshold; clinical cut-off or dichotomisation point. A study is classified high risk of
bias if the authors define the optimal cut-off post-hoc based on their own study data
because selecting the threshold to maximise sensitivity and / specificity may lead to
overoptimistic measures of test performance.
Certain papers may use an alternative methodology for analysis that does not use
thresholds and these papers should be classified as not applicable.
Reference Standard
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 Is the assessment used
for clinical diagnosis of
dementia acceptable?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Commonly used international criteria to assist with clinical diagnosis of dementia
include those detailed in DSM-IV and ICD-10. Criteria specific to dementia subtypes
include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia;
McKeith criteria for Lewy Body dementia; Lund criteria for frontotemporal dementia;
and the NINDS-AIREN criteria for vascular dementia. Where the criteria used for
assessment is not familiar to the review authors or the Cochrane Dementia and
Cognitive Improvement group (‘unclear’) this item should be classified as “high risk
of bias”.
 
Was clinical assessment
for dementia performed
without knowledge of the
PIB-PET biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are sufficient
and full details of the blinding procedure are not required. Interpretation of the results
of the reference standard may be influenced by knowledge of the results of index
test.
Patient flow
Was there an appropriate
interval between PIB-PET
biomarker and clinical
dementia assessment?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
As we test the accuracy of the PIB-PET biomarker for MCI conversion to dementia,
there will always be a delay between the index test and the reference standard
assessments. The time between reference standard and index test will influence the
accuracy ( Geslani 2005 ; Okello 2009 ; Visser 2006 ), and therefore we will note
time as a separate variable (both within and between studies) and will test its
influence on the diagnostic accuracy. We have set a minimum mean time to follow-
up assessment of 1 year. If more than 16% of subjects of subjects have assessment
for MCI conversion before nine months this item will score ‘no’.
Did all subjects get the
same assessment for
dementia regardless PIB-
PET biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
There may be scenarios where subjects who score “test positive” on index test have
a more detailed assessment. Where dementia assessment differs between subjects
this should be classified as high risk of bias.
 
Were all patients who
received PIB-PET
biomarker's assessment
included in the final
analysis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
If the number of patients enrolled differs from the number of patients included in the
2X2 table then there is the potential for bias. If patients lost to drop-outs differ
systematically from those who remain, then estimates of test performance may
differ.
If drop outs these should be accounted for; a maximum proportion of drop outs to
remain low risk of bias has been specified as 20%
 
Were missing PIB-PET
biomarker results
reported?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where missing or uninterpretable results are reported, and if there is substantial
attrition (we have set an arbitrary value of 50% missing data), this should be scored
as ‘no’. If those results are not reported, this should be scored as ‘unclear’ and
authors will be contacted
Anchoring statements to assist with assessment for applicability
Question Explanation 
 
Were included patients
representative of the
general population of
interest?
The included patients should match the intended population as described in the review question.
The review authors should consider population in terms of symptoms; pre-testing; potential
disease prevalence; setting 
If there is a clear ground for suspecting an unrepresentative spectrum the item should be rated
poor applicability.
Index test
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Were sufficient data on
Plasma and PIB-PET
biomarker's application
given for the test to be
repeated in an
independent study?
 
Variation in technology, test execution, and test interpretation may affect estimate of accuracy. In
addition, the background, and training/expertise of the assessor should be reported and taken in
consideration. If PIB-PET biomarker was not performed consistently this item should be rated
poor applicability.
Reference Standard
 
Was clinical diagnosis of
dementia made in a
manner similar to current
clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed
the dementia diagnosis. For certain reviews an applicability statement relating to reference
standard may not be applicable. There is the possibility that a form of dementia assessment,
although valid, may diagnose a far larger proportion of subjects with disease than usual clinical
practice. In this instance the item should be rated poor applicability.
Graphs
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